 Protocol Version 2.0 
 Page 1 of 70 Protocol Title:  A Phase Ib/II, single center, placebo-controlled, 
randomized, blinded study in adult patients (> 18 years) 
with COVID-19 Respiratory Disease, to evaluate, S afety, 
Tolerability and mechanistic effect of Alvelestat on top of 
standard of care (COSTA)  
Protocol Title:  Abbreviated: CO VID-19 Phase Ib/II  Study of Safety and 
Tolerability of Alvelestat (COSTA)  
Protocol Number:  COSTA 
IND:  151665 
NCT identifier:  [STUDY_ID_REMOVED]  
Compound Number:  Alvelestat/MPH966 (formerly AZD9668)  
Principal Investigator: Dr Mike Wells  
Sponsor Name and Legal Registered Address:  University of Alabama, Birmingham, 701 20
th Street 
South, AB 1170, Birmingham, AL 35294- 0111, USA  
 
 
 
 Protocol Version 2.0 
 Page 2 of 70 TABLE OF CONTENTS  
TABLE OF CONTENTS  ..............................................................................................................2  
LIST OF FIGURES  .......................................................................................................................4  
1.0 SYNOPSIS  ..........................................................................................................................5  
2.0 SCHEDULE OF ASSESSMENTS (SOA)  .......................................................................9  
3.0 INTRODUCTION............................................................................................................12  
3.1 Background ............................................................................................................12  
3.2 Study Rationale ......................................................................................................12  
4.0 OBJECTIVES AND ENDPOINTS  ................................................................................14  
5.0 STUDY DESIGN  ..............................................................................................................15  
5.1 Overall Desi gn and Purpose...................................................................................15  
5.2 Number of Participants ..........................................................................................17  
5.3 End of Study Definition .........................................................................................17  
5.4 Scientific Rationale for Study Design ....................................................................17  
5.5 Justification for Dose .............................................................................................18  
5.6 Preclinical Safety Studies  ......................................................................................19  
5.7 Clinical Safety Studies  ...........................................................................................20  
5.8 Benefit-Risk Assessment  .......................................................................................22  
6.0 STUDY POPULATION ..................................................................................................24  
6.1 Inclusion Criteria  ...................................................................................................24  
6.2 Exclus ion Criteria  ..................................................................................................24  
6.3 Lifestyle Restrictions  .............................................................................................26  
6.3.1  Meals and Dietary Restrictions  .............................................................26  
6.3.2  Alcohol and Tobacco ............................................................................26  
6.3.3  Activity  ..................................................................................................26  
6.4 Screen Failures  .......................................................................................................26  
7.0 TREATMENTS ................................................................................................................26  
7.1 Treatments Administered  .......................................................................................27  
7.2 Method of Treatment Assignment .........................................................................27  
7.3 Blinding..................................................................................................................27  
7.4 Preparation/Handling/Storage/Accountability .......................................................27  
7.5 Treatment Compliance  ...........................................................................................28  
7.6 Concomitant Therapy.............................................................................................28  
7.7 Treatment After the End of the Study ....................................................................28  
8.0 DISCONTINUATION CRITERIA ................................................................................29  
8.1 Discontinuation of Study Treatment ......................................................................29  
 Protocol Version 2.0 
 Page 3 of 70 8.1.1  Temporary Discontinuation ..................................................................31  
8.1.2  Dose De -escalation due to Study Drug Intolerance ..............................32  
8.1.3  Re-challenge  ..........................................................................................32  
8.2 Discontinuation from the Study .............................................................................33  
8.3 Lost to Follow-up ...................................................................................................33  
9.0 STUDY ASSESSMENTS AND PROCEDURES  ..........................................................34  
9.1 Key Screening Assessments ..................................................................................34  
9.2 Efficacy Assessments .............................................................................................34  
9.2.1  Blood Biomarkers .................................................................................34  
9.2.2  SaO 2/FiO 2 (Oxygen saturation/fraction inspired oxygen ......................35  
9.3 Clinical Outcome Efficacy Measurements  ............................................................35  
9.3.1  Effect on disease progression recorded as participant status ................36  
9.3.2  WHO 9 -Point Ordinal Scale  .................................................................36  
9.4 Safety Assessments  ................................................................................................36  
9.4.1  Physical Examinations ..........................................................................36  
9.4.2  Vital Signs  .............................................................................................37  
9.4.3  Headache  ...............................................................................................37  
9.4.4  Clinical Safety Laboratory Assessments  ...............................................37  
9.4.5  Data Monitoring ....................................................................................38  
9.5 Adverse Events  ......................................................................................................38  
9.5.1  Time Per iod and Frequency for Collecting AE and SAE 
Information  ............................................................................................38  
9.5.2  Follow-up of an AE and/or SAE ...........................................................38  
9.5.3  Adverse Events of Special Interest  .......................................................39  
9.5.4  Regulatory Reporting Requirements for SAE.......................................40  
9.5.5  Pregnancy  ..............................................................................................40  
9.6 Treatment of Overdose  ..........................................................................................40  
9.7 Pharmacokinetics  ...................................................................................................41  
9.8 Pharmacodynamics  ................................................................................................41  
10.0  STATISTICAL CONSIDERATIONS  ...........................................................................41  
10.1  Sample Size Determination ....................................................................................41  
10.2  Populations for Analyses .......................................................................................42  
10.3  Statistical Analyses  ................................................................................................42  
10.3.1  Safety Analyses (Primary Endpoint) .....................................................44  
10.3.2  Efficacy Analyses (Secondary Endpoints) ............................................45  
10.3.3  PK Analyses  ..........................................................................................46  
 Protocol Version 2.0 
 Page 4 of 70 10.3.4  Interim Analyses  ...................................................................................46  
11.0  REFER ENCES  .................................................................................................................47  
12.0  APPENDICES  ..................................................................................................................50  
APPENDIX 1:  ABBREVIATIONS, TRADEMARKS & GLOSSARY  .................................50  
APPENDIX 2:  CLINICAL LABORATORY TESTS  .............................................................53  
APPENDIX 3:  STUDY GOVERNANCE CONSIDERATIONS  ............................................54  
APPENDIX 4:  ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW -UP, AND REPORTING  .......................57  
APPENDIX 5:  CONTRACEPTIVE GUIDANCE AND COLLECTION OF 
PREGNANCY INFORMATION ...................................................................................62  
APPENDIX 6:  WORLD HEALTH ORGANISATION 9 -POINT ORDINAL SCALE  .......66  
APPENDIX 7:  COMMO N TERMINOLOGY CRITERIA FOR ADVERSE EVENTS  .....67  
APPENDIX 8:  STUDY ORGANIZATION ..............................................................................68  
APPENDIX 9:  SUMMARY OF VERSIONS AND CHANGES  .............................................69  
 
LIST OF FIGURES  
Figure 1:  Study Schematic.....................................................................................................16  
 
 Protocol Version 2.0 
 Page 5 of 70 1.0 SYNOPSIS  
Protocol Title : A Phase Ib /II, single center , placebo-controlled, randomized study in adult 
patients ( >18 years) with COVID-19 Respiratory Disease, to evaluate, Safety,  Tolerability and 
mechanistic effect of Alvelestat on top of standard of care (COSTA) . 
Rationale : Neutrophils and neutrophil extracellular traps (NETs) have recently been established 
as a central feature of S ARS -CoV-2 pathogenesis, and NET formation (NETosis) are associated 
with poor outcomes in patients hospitalized with COVID-19 ( Zuo et al  2020 ; Barnes et al  2020). 
NETs are networks of extracellular DNA fib ers, histones, myeloperoxidase (MPO) and 
neutrophil elastase (NE), released from neutrophils and involved physiologically in capturing 
bacteria. However, if uncontrolled, NETs are cytotoxic to endothelial and epithelial cells, acting as Damage Associated Molecular Pattern Molecules (DAMPs)  and promoting cytokine release 
and thromboses ( Kim et al  2019). Levels of NETs correlate with disease severity in ALI/ARDS 
(Li et al 2018) Neutrophil elastase is essential to NET formation (Papayannopoulos et al  2010) 
and remains active when decorating the NET fiber s. The physiological inhibitor of NE is Alpha-
1 antitrypsin (AAT), but studies in COVID-19 have shown this to be overwhelmed  (McElv aney et al 2020). Providing NE inhibition therefore has potential to reduce both NET 
formation and damaging activity of existing NETs. In experimental model s of ARDS, alvelestat, 
the NE inhibitor proposed for this clinical trial, protected the lung from inflammation and injury through NET inhibition ( Li et al 2018). There is  also evidence from clinical efficacy studies 
using NE inhibitors in ALI/ARDs. Sivelestat (‘Elastpol’) is a selective human neutrophil elastase inhibitor that is approved in Japan and South Korea for the treatment of ALI/ARDS accompanied by Systemic Inflammator y Response Syndrome. A meta -analys is of 6 randomised controlled 
trials in patients with all forms of ALI/ARDS, did  not demonstrate an effect on mortality, 
Intensive Care Unit (ICU) or ventilator days. However, a sensitivity analysis detected a significant improvement in oxygen deficit measured by PaO2/FiO2 (SMD: 0.87; 95% CI: 0.39 to 
1.35; P < 0.001, ( Pu et al 2017) and oxygenation of Day 3 ( Iwata et al 2010 ). Sivelestat appeared 
to have an effect on mortality in ARDS associated with disseminated intravascular coagulation 
(DIC) (Miyoshi et al  2014) , a neutrophil-predominant disease, which is more closely aligned 
with COVID, and provides support for the NE mechanism.  
Alvelestat  (MPH966, AZD9668) is an oral, specific, potent human NE inhibitor ( Stevens  et al  
2011). Alve lestat effectively inhibits neutrophil elastase activity in man, including during 
maximal neutrophil stimulatio n. It shows predictable systemic pharmacokinetic (PK) profile and 
therapeutically relevant concentrations in sputum ( Gunawardena et al 2013) . Clinical safety and 
efficacy experience has been gained in over 1000 healthy volunteers and patients with lung 
disease, including Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis and bronchiectasis ( Kuna et al 2012; Elborn et al 2012; Stockley  et al 2013). There has been 
evidence of mechanistic effect in clinical studies of neutrophil -driven diseases, with significant 
decrease in biomarkers of elastase activity in cystic fibrosis  (Elborn et al 2012), and clinically 
significant improvement in lung function (Forced Expiratory Volume in 1 second [ FEV1 ]) in 
bronchiectasis  (Stockley et al 2013), with reduction in the pro-inflammatory biomarkers 
 Protocol Version 2.0 
 Page 6 of 70 Interleukin (IL)- 6 and RANTES  in sputum and blood observed in both these studies. Alvelestat 
is currently being investigated in ongoing clinical trials in alpha-1 antitrypsin deficiency lung 
disease (Clinical Trials.Gov [STUDY_ID_REMOVED]; [STUDY_ID_REMOVED]) and  Bronchiolitis Obliterans 
Syndrome associated with chronic graft versus host disease ([STUDY_ID_REMOVED]).  
The scientific rationale for NE inhibition in SARS -CoV-2 infection, the evidence for an effect in 
other inflammatory lung diseases and the safety profile for alvelestat , supports investigating 
alvelestat in COVID -19. Here, we propose a pilot randomized, placebo-control led trial assessing 
the safety and tolerability and exploring mechanistic effect on NETosis and clinical outcomes of 
alvelestat given on top of standard of care, compared  to standard of care alone in patients 
hospitalized with COVID -19.   
Overall Purpose and Design:  
The purpose of this study is to evaluate t he safety, tolerability,  PK and  explore mechani sm of 
action  and clinical  effect of alvelestat in patients hospitalized with proven COVID-19 lung 
disease.   
This is a Phase Ib/II single-center, 2:1 randomized, blinded, placebo -controlled, parallel group, 
first in disease study. The objectives are  to determine the safety , tolerability and PK and  to 
explore the mechanistic and clinical effect of the NE inhibitor alvelestat , 240mg orally twice per 
day for 5 or 10 days added to standard of care (SoC) versus placebo added to SoC, in  adult 
patients ( ≥18 years) with COVID-19 respiratory disease.  
 Protocol Version 2.0 
 Page 7 of 70 Objectives and Endpoint s: 
Objective  Endpoint  
Primary  
• To evaluate  the safety and 
tolerability  of alvelestat 
administere d twice d aily (bid) 
for 5 or 10 days By treatment group (alvelestat/placebo):  
• Numbers and % of subjects who experience at least 1 
treatment -emergent adverse event  to Day 60 (Safety Outcome 
Assessment)  
• Adverse events of special interest (liver function 
abnormalities, corrected QT interval, infect ions, and 
neutropenia) and clinically significant safety monitoring labs 
tests to EoT  
• Number and % of subjects that discontinue alvelestat to Day 
5 or 10 
• Number and  % of subjects requiring dose reduction to Day 5 
or 10 
• Number and % of subjects with AE of headache on prospective questioning and CTCAE severity Grade to Day 
5 
or 10 
• Change in vital signs, EK G, safety laboratory measures  to 
Day 5 or 10 or EOT 
Secondary  
• To evaluate  the eff ect of 
alvelestat on blood 
pharmacodynamic ma rkers of 
Neutrophil Extracellular Trap (NET) activation, e lastase, 
inflammatory and coagulopathy activity By treatment group (alvelestat/placebo), ch ange from baseline to 
Day 5 or 10 in: 
• Blood biomarkers of NETosis (cell- free DNA ; citrullinated 
histone H3 ; Myeloperoxidase (MPO)-DNA complexes) 
• Blood biomarkers of inflammation ( absolute neutrophil 
count; absolute lymphocyte count; neutrophil- lymphocyte 
ratio [NLR], C -Reactive protein , procalcitonin  
• Pro-inflammatory cytokines IL-1beta, IL- 6, IL -8, TNF -alpha)  
• Coagulopathy as measured by D- Dimer  
• Plasma desmosine/isodesmosine 
• To explore the effect of 
alvelestat on pulmonary function By treatment group (alvelestat/placebo):  
• Change from baseline  to Day 5 or 10 or E oT in SaO2/FiO2  
• The effect of alvelestat on disease progression By treatment group (alvelestat/placebo):  
• Proportion of subjects alive and free of respiratory failure (without need for non -invasive or invasive  mechanical 
ventilation,  high flow  oxygen, or E xtracorporeal Membrane 
Oxygenation (E CMO) at Day 29 
 Protocol Version 2.0 
 Page 8 of 70 Objective  Endpoint  
• The effect of alvelestat on 
clinical outcomes   By treatment group (alvelestat/placebo):  
• Mortality rate at Day 90  safety endpoint  
• Proportion of subjects alive and free of respiratory failure (without need for non- invasive or invasive mechanical 
ventilation,  high flow  oxygen, or ECMO) at Days 5, 10 
and 60 
• Length of hospital sta y 
• Length of ICU stay  
• Time to room air (those on supplemental oxygen at Baseline)  
• The effect of alvelestat on disease severity  By treatment group (alvelestat/placebo):  
• Percentage of patients deteriorating (>1 and >2 increase in WHO 9-point ordinal scale*) at Day 5, Day 10, Day 29 and 
Day 60 
• Percentage of patients improving (>1 and > 2 decrease in 
WHO 9-point ordinal scale) at Day 5, Day 10, Day 29 and 
Day 60 
• To explore Pharmacokinetics 
(PK) in patients with 
COVID-19 • Plasma PK (sparse sampling taken pre or 1-2 hours post 
study drug dosing) in participants randomized to alvelestat.  
 
* WHO 9-point ordinal scale: 
0. Uninfected, no clinical or virological evidence of infection  
1. Ambulatory, no limitation of activities  
2. Ambulatory, limitation of activities  
3. Hospitaliz ed – mild disease, no oxygen therapy  
4. Hospitaliz ed – mild disease, oxygen by mask or nasal prongs  
5. Hospitaliz ed – severe disease, noninvasive ventilation or high flow oxygen  
6. Hospitaliz ed – severe disease, intubation and mecha nical ventilation  
7. Hospitaliz ed – severe disease, ventilation and additional organ support – vasopressors, renal replacement 
therapy, extracorporeal membrane oxygenation  
8. Death  
 
 Protocol Version 2.0 
 Page 9 of 70 2.0 SCHEDULE OF ASSESSMENTS (SOA) 
a) For subjects comple ting treatment at Day 5 
Study period Screening Period Study Treatment Period (once daily assessment for safety, respiratory support 
requirement7, level of hospital care [ward/ICU] and adverse events during 
hospitalization)2 Safety and Efficacy Follow Up Period2 
Visit Name Screening Baseline/ 
Randomize   End of 
Treatment 
(EoT) 8 Safety Follow 
Up (FU) Clinical Outcome 
Assessment 
(COA) Final Safety 
Follow Up 
(FU) 2 Mortality 
Follow Up 
Study Day Day-2 to Day -1 
(screening and 
randomization can 
be on same day) Day 1 Day 2 Days 3 and 4 Day 5 Day 10 
(+/- 2 days) Day 29 
(+/- 2 days) Day 60 
(+/- 4 days) Day 90 
(+/- 7 days) 
Eligibility check X         
Informed consent X         
Medical History  X         
Randomization  X         
Physical exam (full at 
screening, limited thereafter) X X X X X X    
Study Drug dosing   X  X  X  X      
Interim history, concomitant med, and adverse event 
recording
1, 2 X X X X X X X5 X5  
Prospective headache query  X    X      
Pregnancy test (high sensitivity 
serum at screening, urine 
thereafter) 9 X     X    
Blood draw (screening and in-
study safety monitoring)2, 9 X X   X  X     
 
 
 Protocol Version 2.0 
 Page 10 of 70 Visit Name Screening Baseline/ 
Randomize   End of 
Treatment 
(EoT) Safety 
Follow Up 
(FU) Clinical 
Outcome 
Assessment 
(COA) Final Safety 
Follow Up 
(FU) 2 Mortality 
Follow Up 
Study Day Day-2 to Day -1 
(screening and 
randomization can 
be on same day) Day 1 Day 2 Days 3 and 4 Day 5 Day 10 
(+/- 2 days) Day 29 
(+/- 2 days) Day 60 
(+/- 4 days) Day 90 
(+/- 7 days) 
Blood draw (biomarkers)  X    X     
SaO2/FiO2  X  X X X     
Blood (PK)3  X   X6     
EKG2,4 X  X   X6     
Progression Endpoint  
(alive and free of respiratory 
failure, respiratory support 
level7)     X X  X5  
Clinical outcomes assessments including WHO 
ordinal scale assessment  X  X  X  X X X5 X5 X5,10 
1 Only SAEs to be collected prior to randomization 
2 Investigations and examination performed as part of routine cl inical assessment of COVID-19 may be used for eligibility and i n study safety, advers e event and respiratory support requireme nt 
assessment 
3 Time of PK and last dose of stu dy medication prior to PK to be recorded in CRF 
4 EKG to be taken 1-2 hours after study drug dosing when feasibl e 
5 Telehealth visit if hospital discharge occurs before scheduled  visit  
6 PK and EKG can be taken on any one of Days 3-5 
7 Level of respiratory support dete rmined by need for room air, s upplemental oxygen, high flow oxygen, non-invasive ventilation, intubation, mechanical ventilation or ECMO 
8 Subjects who terminate study Befo re Day 5 should have EOT asses sment and Safety Follow Up assessm ent 5 days +/- 2 days after l ast dose of study drug 
9 If Screening and baseli ne are within 24 hours the tests do not need to be repeated at Baseline 
10 Clinical outcome assessment of mortality only 
 Protocol Version 2.0 
 Page 11 of 70 b) For subjects extending study drug to Day 10 
Study period Treatment Period Safety and Efficacy Follow Up Period2 
Visit Name Extension PeriodEnd of 
Treatment (EoT)Safety Follow Up Clinical Outcome 
Assessment (COA) Final Safety Follow 
Up (FU) 4 Mortality Follow Up
Study Day Days 6 to 9 Day 10 Day 15 +/- 2 days Day 29 
(+/- 2 days) Day 60 
(+/- 4 days) Day 90 
(+/- 7 days) 
Limited Physical exam  X X X    
Study Drug dosing  X  X      
Interim history, concom itant med, and adverse 
event recording1, 2 X X X X5 X5  
Prospective headache query   X     
Pregnancy test (urine)   X    
Blood draw  
(in-study safety monitoring)2 X X X    
Blood draw (biomarkers)  X     
SaO2/FiO2 X X X    
EKG2,4  X X6    
Progression Endpoint (alive and free of respiratory 
failure, respiratory support level7)  X   X5  
Clinical outcomes asse ssments including WHO 
ordinal scale assessment X X X X5 X5 X5,8 
1 Only SAEs to be collected prior to randomization 
2 Investigations and examination performed as part of routine cl inical assessment of COVID-19 may be used for eligibility and i n study safety, adverse event and respiratory support 
requirement assessment 
3 Time of PK and last dose of stu dy medication prior to PK to be recorded in CRF 
4 EKG to be taken 1-2 hours after study drug dosing when feasibl e 
5 Telehealth visit if hospital discharge occurs before scheduled  visit  
6 PK and EKG can be taken on any one of Days 3-5 
7 Level of respiratory support dete rmined by need for room air, s upplemental oxygen, high flow oxygen, non-invasive ventilation, intubation, mechanical ventilation or ECMO 
8 Clinical outcome assessment of mortality only 
 Protocol Version 2.0 
 Page 12 of 70 3.0 INTRODUCTION 
3.1 Background 
Infection with the SARS -CoV-2 virus has led to the coronavirus disease 2019 (COVID- 19) 
pandemic, affecting global health and economies on an unprecedented scale ( Zhu et al 20 20; 
Holshue et al 2020; Goyal et al 2020). The spectrum of illness ranges from asymptomatic to 
critical, with mild symptoms in ~80% of cases. However, severe disease is characterized by 
dyspnea, hypoxemia, and respiratory failure with acute respiratory distress syndrome (ARDS), shock, and multi-organ failure. As of June 10, 2020, the World Health Organization reported that there are over 7.2 million cases of COVID-19 worldwide, accounting for nearly 413,000 deaths (World Health Organization | COVID-19 Situation Report 142, June 2020). While the use of 
stay-at-home orders, social distancing, and deployment of limited business models have resulted 
in a “flattening of the curve”, the number of new cases and deaths continue to rise and there are limited therapeutic options. To date there are no approved therapies for SARS-CoV-2 infection, though antiviral medications have shown the most promise ( Grein  et al 2020 ; Cao et al 2020). 
Other strategies have included targeting host inflammatory pathways or repurposing existing medications, but these have not been successful in early trials ( Geleris  et al 2020; Ingraham et al 
2020; Mercuro et al 2020). Emerging data demonstrated reduced mortality with use of 
dexamethasone from a placebo -controlled trial ( Horby et al 2020). The evidence of 
immunopathogenesis of COVID-19 disease supports the potential of intervention with immunomodulators in addition to the efforts in anti-viral therapy.
 
3.2 Study Rationale 
The clinical course of COVID -19 is characteri zed by initial symptoms typical of viral infection. 
In some individuals, this is followed several days later by rapid deterioration, concurrent with the onset of the immune response ( Ingraham et al 2020). An acute innate inflammatory response is 
typical, with elevated pro-inflammatory cytokines, marked ele vation of acute phase reactants and 
cytokine storm. Available therapies consist of organ support, anti-coagulation to reduce risk of venous and arterial thrombosis, and as needed treatment of infection and sepsis. Repurposed’ existing immunomodulating ther apies are being progressed through global ‘platform’ trials, 
including for anti-IL6, anti-IL1, dexamethasone and hydroxychloroquine, with results emerging. None are specifically targeting neutrophil-driven pathogenic mechanisms. 
Neutrophils and neutrophil extracellular traps (NETs) have recently been established as a central feature of SARS -CoV-2 pathogenesis, and NETosis is associated with poor outcomes in patients 
hospitalized with COVID -19 ( Zuo et al 2020; Barnes et al 2020 ). Levels of NETs correlate with 
disease severity in ALI/ARDS outside of COVID-19. NETs are networks of extracellular DNA fibers, histones, myeloperoxidase (MPO) and neutrophil elastase (NE), released from neutrophils and involved physiologically in capturing bacteria. However, if uncontrolled, NETs are cytotoxic to endothelial and epithelial cells; acting as Damage Associated Molecular Pattern Molecules (DAMPs), promoting cytokine release and thromboses ( Kim et al  2019). Neutrophil elastase is 
essential to NET formation ( Papayannopoulos et al 2010) and remains active when decorating 
 Protocol Version 2.0 
 Page 13 of 70 the NET fib ers. The physiological inhibitor of NE is Alpha-1 antitrypsin (AAT), but studies in 
COVID-19 have shown this to be overwhelmed ( McElv aney et al 2020) and treatment with NE 
inhibitors have potential to impact the disease progression to ARDS through disruption of 
NETosis. In experimental models of ARDS, alvelestat, the NE inhibitor proposed for this clinical 
trial, protected the lung from inflammation and injury through NET inhibition  (Li et al 2018). 
There is evidence from clinical efficacy studies using NE inhibitors in ALI/ARDs. Sivelestat (‘Elastpol’) is a selective human NE inhibitor that is approved in Japan and South Korea for the treatment o f ALI/ARDS accompanied by Systemic Inflammatory Response Syndrome. A meta-
analysis of 6 randomized controlled trials in patients with all forms of ALI/ARDS, did not demonstrate an effect on mortality, Intensive Care Unit or ventilator days. However, a sens itivity 
analysis detected a significant improvement in oxygen deficit measured by PaO2/FiO2 (Standardized Mean Difference (SMD) : 0.87; 95% CI: 0.39 to 1.35; p <0.001 ( Pu et al 2017) and 
oxygenation at Day 3 ( Iwata et al 2010). Sivelestat appeared to have an effect on mortality in 
ARDS associated with disseminated intravascular coagulation ( Miyoshi et al  2014), which is 
more closely aligned with pathogenic processes in COVID-19, and provides support for the NE mechanism.  
 
Alvelestat is an oral, specific, NE inhibitor, with experience in over 1000 healthy volunteers and patients with lung disease. There has been evidence of mechanistic effect in 4-week duration 
clinical studies of neutrophil- driven diseases (significant decrease in biomarkers of elastase 
activity  and inflammation in cystic fibrosis ( Elborn et al 2012), and clinically significant 
improvement in lung function and inflammation  in bronchiectasis ( Stock ley et al 2013). 
A scientific rationale for NE inhibition in SARS -CoV-2 infection, plus the established safety 
profile for alvelestat supports investigating alvelestat in COVID -19. Here, we propose a pilot 
randomized control trial assessing the safety and tolerability and exploring biomarkers of efficacy and clinical  outcomes, by comparing alvelestat on top of standard of care compared to 
placebo  on top of standard of care in patients hospitalized with COVID -19.  
 
The specific objectives  of this study are to evaluate the safety and tolerability of alvelestat in this 
first time in disease study , confirm PK  and explore evidence for mechanistic eff ect on NETosis 
and clinical outcomes  in patients with COVID-19 respiratory disease. The pathogenesis of 
COVID-19 is complex, where multiple pathogenic mechanisms are in play and this study will explore the potential role of NE inhibition. Positive data from this Phase Ib/II trial will support 
progression to a formal dose-ranging efficacy study, informed by safety, tolerability and PK in 
the COVID -19 population. 
 
Alvelestat is a potent and specific inhibitor of NE, has predicable PK and an established PK/PD 
relationship in ex vivo  neutrophil elastase inhibition (Gunawardena et al  2013). This enables  a 
dose to be chosen to fully test the mechanism in COVID-19 disease. Relevant blood biomarkers 
will be used to detect signals of effect. Blood biomarkers of NETosis , cell -free DNA  (cf-DNA), 
citrullinated -H3 and MPO- DNA complexes are available. These are elevated in hospitalized 
COVID-19 patients and correlate with disease severity  Cell -free -DNA and MPO -DNA 
complexes correlat e with acute phase response, C- reactive protein , D-dimers, and neutrophil 
 Protocol Version 2.0 
 Page 14 of 70 count , whereas  citrillunated -H3 with platelet count ( Zuo et al 2020). N eutrophil elastase activity  
is measurable by the elastic breakdown product desmosine/isodesmosine, Effects on m arkers of 
inflammatio n, proinflammatory cytokines (IL -1beta, IL- 6, IL -8 and TNF- alpha) and 
coagulopathy (d -dimer) will explore whether the inhibitory effect of alvelestat on neutrophil 
elastase/NETs  delivers potential benefit on the downstream inflammatory and vascular 
processes . These mechanistic effects data in combination with safety and tolerability and 
predictability of PK, will be used to make progression decisions on alvelestat development in 
COVID-19 disease.  
4.0 OBJECTIVES AND ENDPOINTS  
Objective  Endpoint  
Primary  
• To evaluate  the safety and tolerability 
of alvelestat administere d twice d aily 
(bid)  for 5 or 10 days By treatment group (alvelestat/placebo):  
• Numbers and % of subjects who experience at least 1 
treatment -emergent adverse event to Day 60 (Safety 
Outcome Assessment)  
• Adverse events of special interest (liver function abnormalities, corrected QT interval, infections, and 
neutropenia) and clinically significant safety 
monitoring labs tests to Day 14 (acute treatment 
period) or EoT  
• Number and % of subjects th at discontinue alvelestat 
to Day 5 or 10 
• Number and % of subjects requiring dose reduction to Day 5 or 10 
• Number and % of subjects with AE of headache on 
prospective questioning and CTCAE severity Grade 
to Day 5 or 10 
• Change in vital signs, EKG, safety laboratory 
measures to Day 5 or 10 or EOT  
Secondary  
• To evaluate  the eff ect of a lvelestat on 
blood pha rmacodynamic markers of 
Neutrophil Extracellular Trap (NET) 
activation, e lastase, inflammatory and 
coagulopathy acti vity By treatment group (alvelestat/placebo), ch ange fr om 
baseli ne to Day 5 or 10 in: 
• Blood biomarkers of NETosis (cell -free DNA; 
citrullinated histone H3; Myeloperoxidase (MPO) -
DNA complexes)  
• Blood biomarkers of inflammation (absolute 
neutrophil count; absolute lymphocyte count; neutrophil -lymphocyte ratio [NLR], C -Reactive 
protein, procalcitonin 
• Pro-inflammatory cytokines IL -1beta, IL -6, IL -8, 
TNF -alpha)  
• Coagulopathy as measured by D -Dimer  
• Plasma desmosine/isodesmosine 
 Protocol Version 2.0 
 Page 15 of 70 Objective  Endpoint  
• To explore the effect of alvelestat on 
pulmonary function By treatment group (alvelestat/placebo):  
• Change from baseline to Day 5 or 10, or EoT in 
SaO2/FiO2  
• The effect of alvelestat on disease progression By treatment group (alvelestat/placebo):  
• Proportion of subjects alive and free of respiratory 
failure (without need for non-invasive or invasive mechanical ventilation, high flow oxygen, or 
Extracorporeal Membrane Oxygenation (ECMO) at Day 29 
• The effect of alvelestat on clinical outcomes  By treatment group (alvelestat/placebo):  
• Mortality rate to Day 90  safety endpoint  
• Proportion of subjects alive and free of respiratory 
failure (without need for non -invasive or invasive 
mechanical ventilation,  high flow  oxygen, or 
ECMO) at Days 5, 10 and 60 
• Length of hospital stay  
• Length of ICU stay 
• Time to room air (those on supplemental oxygen at Baseline)  
• The effect of alvelestat on disease severity  By treatment group (alvelestat/placebo):  
• Percentage of patients deteriorating (>1 and >2 
increase in WHO 9 -point ordinal scale*) at Day 5, 
Day 10, Day 29 and Day 60 
• Percentage of patients improving (>1 and >2 decrease in WHO 9 -point ordinal scale) at Day 5, 
Day 10, Day 29 and Day 60 
• To explore Pharmacokinetics (PK) in 
patients with COVID-19 • Plasma PK (sparse sampling taken pre or 1 -2 hours 
post study drug dosing) in participants randomized to alvelestat.  
 
5.0 STUDY DESIGN  
5.1 Overall  Design  and Purpose  
This is a Phase Ib /II single-center, 2:1 randomized, blinded, placebo-controlled, parallel group, 
first in disease study. The purpose is to determine the safety, tolerability and PK and explore the 
mechanistic and clinical effect of alvelestat 240mg orally twice per day for 5 or 10 days added to 
standard of care in adult patients ( ≥18 years) with COVID-19 respiratory disease.  
The study is divided into 3 periods :  a screening period, treatment period, and follow up period 
(Figure 1 ) 
 Protocol Version 2.0 
 Page 16 of 70 Figure 1: Study Schematic  
 
 
• A screening p eriod from Day  -2 to randomization.  Eligibility assessments and written 
informed consent will occur prior to randomization and treatment arm allocation.  Serious 
Adverse Events will be collected during screening.  
• A treatment period  consisting of alvelestat /matched placebo 240 mg/matched placebo  bid 
Days 1 to 5 given on top of standard of care (SoC – per local clinical guid elines ). Safety 
assessments including vital signs, liver and renal function, EKG, and hematology will be 
assessed at baseline,  then as per the Schedule of Assessments (SoA)  for the remainder of the 
5-day treatment period. Adverse events , vital signs, respiratory support and concomitant 
medications that may be part of routine clinical care will be collected daily  during 
hospitalization. Blood will be collected at baseline and during study drug treatment to Day 5 
for secondary efficacy biomarkers, along with assessment of oxygen deficit assessments 
(SaO2/FiO2) . PK sampling will be collected on 2 occasions, at initiation of dosing and at end 
of treatment ( EoT) for steady state an alysis.  For patients that remain hospitalized at Day 5 
due to COVID-19, an optional extension period of treatment to Day 10 may be given and can 
be referred to on the separate SOA covering this extension. C linical outcome s of disease 
progression (respiratory support requirements), disease severity (WHO ordinal scale) , will be 
completed at Baseline (Day 1), during the treatment period to ( Day 5 or 10 ), or EoT and to 
Day 60 (Clinical Outcome Assessments) . Those subjects who are unable to complete the 
treatment period  for any reason, including those discharged from hospital prior to completion 
of Day 5 or 10, will discontinue study drug and undergo an EoT assessment . Wherever 
possible they will continue to be followed up in the study.  
Including optional treatment 
extension to Day 10:  
 Protocol Version 2.0 
 Page 17 of 70 • A follow- up period from Day 5 or 10/EoT to Day 90. This is for safety testing to end of 
systemic drug exposure (Day 10 for 5-day study, Day 15 for 10-day study or 5 days after 
EoT) , to Day 60 for longer term safety and to Day 90 for mortality data collection , for the 
Clinical Outcome Asses sment s (COA) to Day 60) and mortality (Day 90) . Visits after 
Day 10 or Day 15 (or 5 days +/ - 2 days after last dose), may be by telehealth visits. Adverse 
events, vital signs, respiratory support and concomitant medications that may be part of routine clinical care will be collected daily during hospitalization  and to the Day 29 and 
Day 60 assessments (may be collected by telehealth call).  
 
5.2 Number of Participant s 
Approximately 20 subjects will be screened in order to recruit  15 (10 randomized to alvelestat + 
SoC; 5 randomized to SoC) . Subjects who discontinue study drug or the study will not be 
replaced.
 
5.3 End of Study  Definition  
The end of the study is def ined as th e date of all data being entered into the study database. The 
primary analysis of safety, biomarker and clinical outcomes efficacy will be performed  when the 
last subject has completed Day 60 follow up, with the database being locked and ready for 
analysis . The Day 90 mortality data will continue to be collected and added to the database and 
reported separately . 
5.4 Scientific Rationale for Study Design  
As the first study of alvelestat in the COVID -19 patient population, investigation of safety and 
tolerability are the primary objectives , and are appropriately investigated in a small 15 subject 
study. Given the severe nature of COVID-19, alvelestat  or identical placebo  will be dosed on top 
of full standard of care. A blinded, placebo -controlled design will support interpretation of 
safety , tolerability and efficacy biomarkers . Historic comparators were not considered  as the 
evolution of the pandemic and changing management of COVID -19 means that a placebo arm 
recruited in parallel is a more robust approach.   
Neutrophils and NETosis play a critical role in the acute inflammatory response and the most 
appropriate time to intervene is early in its initiation, to reduce the risks of further progression. Therefore, the target population is those with prove n SARS -CoV-2, requiring hospitalization, 
with evidence of pulmonary disease on chest radiograph or Computerised Tomography (CT) or other relevant imaging , but not progressed to severe disease ( i.e. not requiring mechanical 
ventilation or with multi-organ failure) at the point of recruitment. This population is known to have an acute phase response and evidence for neutrophil activation (raised CRP and absolute neutrophilia, with activation of the NETosis pathway ( Zuo et al 2020), therefore giving potential 
to detect a mechanistic signal in the study.  At this stage neutrophil elastase may be a key 
pathogenic driver and its inhibition stand the greatest chance of success.   
 Protocol Version 2.0 
 Page 18 of 70 The duration of dosing will be for 5 days with optional extension to 10 days for subjects who 
remain hospitalized with SARS -Cov2 related disease per investigator decision . Deterioration in 
COVID-lung diseas e in hospitalized patients to intubation is rapid and bimodal with modes as 
3-4 days and 9 days from the date first symptoms recorded ( Argenziano et al 20 20) and  even 
shorter period from date of hospital admission with the most patients worsening within the first 
3 days ( Vultaggio et al 2020). With improvements in management of COVID-19 hospital stays 
have decreased to a mean of 5 days. Therefore, 5 days treatment will provide NE inhibition to 
cover  the critical risk period during hospitalization, with the option to continue to 10 days for 
those who disease remains active requiring ongoing hospitalization by Day 5. 
An within -patient dose-escalation approach commencing at 120 mg bid Day 1, increasing to 
180 mg bid Day 2 and 240 mg bid Days 3 to 10, was previously used  to address tolerability 
(headache)  issues that have been identified for alvelestat. Experience to date is that study drug 
has been well tolerated, and in order to rapidly achieve drug levels during the acute phase of 
COVID-19, study drug will be initiated at 240 mg bid. D ose de-escalation , including to 120 mg 
bid, will be allowed  in protocol- defined circumstances  (Section 8 .1.2) for toleration  as 120 mg 
bid is still predicted to provide adequate NE inhibition. Dose de-escalation below 120 mg bid 
will not be permitted.  
5.5 Justification for Dose  
Oral doses of alvelestat 2 mg to 150 mg have been evaluated in healthy participants. Following 
acceptable safety profile of repeat dosing of 60 mg bid in over 1000 individuals (patients with COPD, cystic fibrosis and bronchiectasis ), doses of 120 mg to 240 mg bid have been progres sed 
into clinical studies in Bronchiolitis Obliterans Syndrome ( BOS ) and alpha -1 antitrypsin 
deficiency ( AATD) l ung disease , dosing for up to 6 months duration with an acceptable safety 
profile.  
Alvelestat  is rapidly absorbed (median time to reach peak concentration 0.5 to 1.5 h), with a 
dose-proportional increase in systemic exposure. The terminal half -life of between 
approximately 5 to 10 hours in patient studies, supports twice daily dosing and enable rapid wash out if any concerns on safety or tolerability for individuals in the study. Multiple dosing shows 
no clinically relevant  accumulation, and the PK profile was generally similar between healthy 
participants and patients with COPD, bronchiectasis and cystic fibrosis, Ca ucasians and Japanese 
(Gunawardena et al  2013 ). It is not expected that PK will show meaningful difference in patients 
with COVID -19 lung disease. Pharmacological ly relevant concentrations of alvelestat are present 
in induced and spontaneous sputum in patients with bronchiectasis  and COPD ( Gunawardena et 
al 2013; Stockley et al 2013). 
Alvelestat  demonstrates dose -dependent pharmacodynamic (PD) profile in inhibition of 
zymosan -stimulated neutrophil elastase activity in ex vivo cells from studies in man . Although at 
plasma alvelestat concentrations of >100 nM, neutrophil elastase inhibition was differentiated 
from that observed on placebo, plasma concentrations >300 nM, were required to give meaningful effects achieving a mean neutrophil elastase inhibition  of greater than 92%. 
 Protocol Version 2.0 
 Page 19 of 70 A Population PK model has been developed and used to simulate doses to meet the required 
exposure >30 0 nM at steady state trough levels over the full dosing period of bid dosing. A dose 
of 240 mg bid  was selected  as the target dose based on predicted trough PK levels >300 nM in 
approximately 90% of participants and within acceptable safety margins  over the full 24-hour 
period. Simulations predict 120 mg bid  to deliver trough PK levels >300 nM in approximately 
50% of participants and 240 mg in approximately 90% of participants. In an ongoing study of alvelestat i n AATD, headache, a known adverse event associated with alvelestat, appears to be 
more frequent in those dosed with 240mg bid and impacts tolerability. Experience to date in this trial is that study drug has been well tolerated, and in order to rapidly achieve drug levels during the acute phase of COVID -19, study drug will be initiated at 240 mg bid. The allowance for dose 
de-escalation (including down to 120 mg bid ) in protocol- defined circumstances  (Section 8.1.2) 
if needed to maintain tolerance.  
As summarized below, the preclinical toxicology studies provide adequate safety margins for progressing to the 240 mg bid dose for 5 or 10 days in this study. The clinical safety experience with alvelestat to date,  including to 240 mg bid, has shown no safety signals that prevent 
progression of the proposed dose in this study. A potential concern around transaminase elevation is monitorable and reversible, there have been no cases of drug induced liver injury. The safety of patients will be managed through the exclusion and inclusion criteria and safety monitoring approach, taking into account the preclinical toxicology data and clinical safety information. 
 
5.6 Preclinical Safety Studies  
The safety margins for alvelestat have been evaluated in  preclinical toxicology studies in two 
rodent and one non-rodent species (up to 6 months in rats, 12 months in dogs, and 3 months in mice ), provi ding adequate co ver for the 10-days dosing.
   
In rats , the no adverse effect level ( NOAE L) was 370 mg/kg/day (1-month gavage) and 
500 mg/kg/day (dietar y 1 to  6-month studies). These were the highest doses studied, and no 
toxicity was observed. 
In dog, 1-, 3-, and 12- month  toxicology studies at doses of 1.2, 12, and 122 mg/kg showed 
limited effect at the intermediate and high dose s, including small decreases in body weight, small 
increases in plasma creatinine and trig lycerides , and minor effects on electrocardiogram ( EKG) 
with a transient increase of the QTc by Van de Water’s correction formula ( QTcV) (<10%). The 
NOAEL was considered to be 122 mg/kg. In telemetered dogs at doses of  50 mg/kg 
(corresponding to a peak plasma concentration of 39.9 µM), a mean increase of 9% (individual increases of 8 % to 14%) in QTcV was seen. 
In mice, alvelestat  was well tolerated at doses up to 2000 mg/kg. Histopathology indicated slight 
focal hepatic necrosis above control. Additional effects in liver included minor increase in 
glycogen vacuolation at 2000 mg/kg, slight hypertrophy in males at 1000 mg/kg, and increased incidence above control of inflammatory foci in females at 1000 mg/kg. A recovery  group 
 Protocol Version 2.0 
 Page 20 of 70 indicated possible reversibility, although the interpretation was difficult due to the low- grade 
change. Overall, focal necrosis is regarded as a no n-specific response in mice, with no signs of 
progression or persistence and the relevance for humans is likely  to be limited.  
Preclinical toxicology findings, with the exception of QTc change, would be expected to be 
driven by area under the curve ( AUC ). Based on preclinical data, a human exposure limit 
corresponding to the AUC at the NOAEL (500 mg/kg) in the rat 6-month study (free AUC of 14.7 µM.h, corresponding to a total human AUC of 25.8 µM.h) is considered as acceptable in clinical studies. Significantly higher exposure levels have been evaluated in dogs for 12 months without any adverse effects.   
The maximum 240 mg bid dose in man is predicted to give an AUC of 23287 nm.h, 
approximately 27.2-fold lower than that at the NOAEL in the 12-month study in dogs and 10.9-fold lower than NOAEL in the 6-month study in rats. The AUC is predicted to be approximately 9-fold below the level where liver findings in mice (increase in background pathology of likely limited relevance to man) were seen.  
The maximum observed concentration following 240 mg bid in man is predicted to be 3840 nM, 
approximately 10-fold lower than the concentration that resulted in small (<10%) changes in QTcV in telemetered dog.     
Alvelestat met criteria  for phototox icity in in vitro test system s and has a potential skin 
phototoxicity risk. Photo- safety precautions will be a dvised during the study. 
Alvelestat is considered not to represent a significant genotoxic risk. Reproductive toxicology 
studies in rats and rabbits do not indicate any effects of alvelestat on male or female fertility or 
embr yofetal development.  
There is a potential for drug interactions. Drugs that are mainly metabolized by CYP2C9 and have a low therapeutic index, require drug levels to be monitored during the dosing period or drugs prohibited. Potential to  interact with OATP1B1 has not been excluded and drugs that are 
substantially reliant on OATP1B1 for metabolism (e.g., enalapril and repaglinide), will be prohibited or clinical monitoring applied during the study drug dosing period. The potential to inhibit P-gp has also not been excluded with risk to reduce intestinal drug absorption. Therefore, 
concomitant oral therapies should not be administered within 1 hour of alvelestat administration. 
For more detailed information on the toxicology and nonclinical safety studies conducted to date, 
please refer to the current Investigator ’s Brochure . 
5.7 Clinical Safety Studies  
Clinical experience comes from 12 completed  healthy volunteer and patient studies in which 
1149 subjects have received at least 1 dose of alvelestat . The highest single dose that has been 
given is 150 mg and the highest repeat dose is 240 mg bid (for 6 months ). In clinical studies, 
540 COPD patients have received 60 mg bid for 3 months and 22 patie nts with bronchiectasis 
 Protocol Version 2.0 
 Page 21 of 70 and 26 patients with cystic fibrosis have received 60 mg bid for 28 days. Completed clinical 
studies to date have not revealed any adverse effects  on blood pressure, EKG, hematology, or 
urinaly sis that could be lin ked to any of the observations in toxicology studies. For clinical 
chemistr y, there has been 1 patient with bronchiectasis with an instance of transient raised 
transaminases and 1 patient with cystic fibrosis with an increase in creatine kinase, alanine 
aminotransferase ( ALT), aspartate aminotransferase ( AST ), and lactate dehydrogenase. 
In the studies in COPD patients , there were 14 instances where patients experienced raised ALT 
or AST to  ≥3 × upper limit of normal ( ULN) across the studied doses ( alvelestat  5, 20, and 60 
mg bid). Although definit ive evidence of dose relationship was lacking, there was a suggestion 
of an increased incidence of liver transaminase elevations in patients on alvelestat  for which 
there were no definitive alternative explanation s. The highest transaminase elevations occurred 
in the highest alvelestat  dose (60 mg bid). There have been no cases of Hy’s law related to 
alvelestat  treatment  reported in any of the studies to date (including up to 240 mg bid). The liver 
abnormalities no ted to date with alvelestat, including from study in AATD- related lung disease 
dosed at up to 240 mg bid (Study MPH966-2-01, [STUDY_ID_REMOVED]) have been infrequent (only 5 liver -related adverse events  have been reported and no SAE s of liver abnormalities have 
been reported in study and values rarely above 3x ULN. Furthermore, all abnormal liver changes 
that have been observed have been reversible either with or without study drug interruption.  
The experience of alvelestat doses of 240 mg bid comes from 3 ongoing clinical studies. In a 
study in patients with bronchioli tis obliterans syndrome associated with chronic graft versus host 
disease following allogenic hematopoietic stem cell transplantation ([STUDY_ID_REMOVED]), doses of up 
to 240 mg bid are being given. To date, 7 patients have received 240 mg bid dose for up to 
6 months. One patient underwent dose reduction to 180 mg bid following a SAE of severe 
gastroenteritis and renal failure that was considered unrelated to alvelestat. A second patient had 
elevation of transaminases with temporary treatment discontinuation  on a dose of 60 mg bid. The 
event was considered related to alvelestat , and drug was restarted  at the dose of 60 mg bid at 
recovery following a 2- week temp orary discontinuation. 
In the ongoing blinded study in AATD- related lung disease (MPH966-2-01, [STUDY_ID_REMOVED]) 
57 participants have been randomized to dat e to alvelestat (either 120 mg bid, 240 mg bid) or 
placebo (1:1:1) for 12 weeks duration. No safety signals have been identified. Of the 57 subjects the most common treatment emergent adverse events (TEAEs) to date are headache 31 events in 
24 subjects (42.1%), followed by nausea 8 events in 7 subjects (12.3%), exacerbation of COPD 6 events in 5 subjects (8.8%), nasopharyngitis and respiratory tract infection, 4 events (7.0%) in 4 subjects each, 3 events in 3 subjects each of dyspepsia, dyspnoea and arthralgia (5.3% for each).  
Tolerability issue of headache, (with migr aneous characteristics) , has been reported more 
frequently in the 240 mg bid/placebo arm than the 120 mg bid/placebo arm . The  headaches  
respond to analgesics or study drug interruption. There have been no elevations in liver enzymes 
of clinical concern, none persisting, meeting protocol discontinuation criteria or Hy’s law. Any observed LFT elevations have been transient, reversible and generally return to  baseline with 
temporary interruption to study drug. 
 Protocol Version 2.0 
 Page 22 of 70 In an Investigator Initiated Study also in AATD- related lung disease [ ATALANTa Stu dy, 
[STUDY_ID_REMOVED]], four teen subjects have been treated in this blinded trial to date  with 120 mg bid 
alvelestat/placebo.  There have been no SAEs r eported in this study to date . There have been no 
deaths in any of the 3 studies doing with 120 mg or 240 mg bid. 
For more detailed information on clinical safety studies conducted to date, please refer to the 
current  Investigator ’s Brochure. 
5.8 Benefit -Risk Assessment  
Patients hospitalized with COVID-19 lung disease have an extremely poor outcome . A study of 
1840 enrolees of Kaiser Permanente healthcare plan s who were hospitaliz ed with COVID -19 
docume nted a case fatality ratio of 23.5% among male inpatients and 14.9% amongst females, 
mortality risk increasing with age for both male and fema le patients ( Lewnard et al 2020 ). Those 
over 65, with co -morbidities of obesity, hypertension, type 2 diabetes, as well as black and Asian 
ethnic groups, are particularly vulnerable. Outside organ support and modest effects of antivirals, 
there are limited therapeutic options currently available in this  very high unmet need population. 
Efficacy  for alvelestat  has been demonstrated in animal models of lung inflammation and 
elastase-induced lung injury. Across clinical studies in COPD, cystic fibrosis, and bronchiectasis, 
there has been some evidence for  effects on elastin breakdown, inflammatory biomarkers, and 
lung function. The extent of these effects was not consistent in all studies. This may be due to the heterogeneity of the pathogenesis and/or the doses used (maximum 60 mg bid) that would not be 
expected to adequatel y inhibit neutrophil elastase, allowing inflammatory “escape ”. Greater 
efficacy and clinical benefit is expected by using a dose of alvelestat to maintain neutrophil 
elastase inhibition throughout the 24-hour period.  
Headache was the most frequently reported Adverse Event ( AE) in 8 of the 12 completed studies 
to date. In healthy volunteer studies, headache was reported more commonly in the al velestat 
group than the placebo group. H eadache was generally mild in intensity (although 1 subject had 
severe headache ), and there was no evidence of a dose–related relationship. In studies with cystic 
fibrosis and bronchiectasis, headache was also generally reported more commonly in the alvelestat group compared to placebo. In the COPD studies, headache remained one of the most 
common AEs reported and was the most commonly reported treatment- related AEs has also been 
the most frequently reported adverse event particularly in the 240 mg bid dose group in study 
MHP966-2-01 in AATD. The headache is manageable, resolving with analgesics or treatment 
cessation.  
In the Phase 2b COPD program, there were 14 reported events of raised ALT or AST to ≥3 × 
ULN across the studied doses (alvelestat) 5, 20, and 60 mg bid); there were no cases of Hy’s law during the treatment period. Although definitive evidence of dose relationship was lacking, there 
was a suggestion of an increased incidence of liver transaminase elevations in patients on alvelestat for which there were no definitive alternative explanations. The highest transaminase 
elevations occurred in the highest alvelestat dose (60 mg bid). Elevations in hepatic biochemistry 
 Protocol Version 2.0 
 Page 23 of 70 assessments (transaminases) observed in patients in the alvelestat studies were confounded by 
alcohol or by concomitant medication, but an effect of alvelestat cannot be excluded  at this time . 
COVID- 19 disease is frequently associated with mild elevations in transaminases with increases 
>ULN of 75% and 2XULN in 45% of hospitalized patients ( Phipps et al 2020). Elevation in 
alkaline phosphatase and total bilirubin  are uncommon, and severe liver damage/failure has not 
been reported to date (Tian  & Ye  2020). However, patients may be on multiple medications with 
the possibility of drug-related hepatotoxicity and greater sensitivity  to any potential effects of 
alvelestat. As mild elevations of transaminases are common, in order to assess for any hepatic 
effects in the target population, participants with transaminases up to 3X ULN will be eligible, 
but only if there is no elevation of bilirubin due to liver dysfunction. In summary , exclusion 
criteria for clinically relevant hepatic disease, close observation and frequent in -study 
monitoring, and study treatment discontinuation criteria are in place to prot ect the safety of the 
subjects and liver abnormalities are included as adverse events of special interest ( AESI ). 
There were no other clinically relevant changes in clinical chemistry data in the completed studies with alvelestat. There were also no clinically relevant changes in urinalysis were 
observed in the completed studies with alvelestat. T here were no changes in EKG or vital signs 
data that indicated a clear treatment effect of alvelestat.  However , in light of the minor changes 
in QTc in the dog toxicology, exclusion criteria and  regular E KG monitoring at the time of peak 
concentrations of study treatment and discontinuation criteria will be applied in the study. 
Clinically significant changes in E KG are also included as an AESI.  
Defects in  ELANE, the gene that encodes neutrophil ela stase, are associated with neutropenia and  
susceptibility to infection. To date, no increases in  rate or severity of infection or neutropenia 
have been reported with alvelestat. However, patients with COVID -19 are susceptible to sepsis 
and may be on immunosuppressive drugs, such as systemic corticosteroids that increase infection 
susceptibility . Patients with neutropenia will be excluded, new onset of neutropenia will 
constitute a patient stopping criterion , and infections will be an AESI  to monitor the safety 
profile in this  population. 
The potential phototoxicity risk will be managed by subject guidance on reducing intense sun 
exposure through covering exposed skin and use of sun block as needed. 
At present, based on the cumulative review of the data and with no new safety issues seen in the 
ongoing studie s with dosing up to 240 mg bid of alvelestat, the benefit- risk balance supports the 
clinical development of alvelestat in COVID-19. The potential or theoretical safety concerns on 
liver function, QTc changes, and susceptibility to infection are manageable through exclusion criteria, monitoring , study treatment discontinuation criteria  
More detailed information about the known and expected benefits  and risks and reasonably 
expected AEs of alvelestat  may be found in the current version of the a lvelestat Investigator’s 
Brochure. 
 Protocol Version 2.0 
 Page 24 of 70 6.0 STUDY POPULATION 
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, are not permitted.  
6.1 Inclusion Criteria  
Participants are eligible to be included in the study only if ALL  of the following criteria apply: 
Type of Participant and Disease Characteristics  
• Male or Female  
• Age ≥18 years 
• Proven SARS-Cov-2 infection (confirmed by PCR from a nasopharyngeal or lower respiratory tract sample  or antigen testing from a nasal sample ) 
• A score of Grade 3 to 5 on the WHO 9 -point Ordinal Scale  
• Male participants must agree to use a highly effective contraception as detailed in Appendix 5 during the treatment period and for at least 4 days after the last dose of study treatment and refrain from donating sperm during this period 
• Female participants are eligible to participate if not pregnant; not breastfeeding; and at least one of the following conditions is met:   
• Not a woman of childbearing potential as defined in Appendix 5  
OR 
• A woman o f childbearing potential who agrees to follow the contraceptive guidance 
in Appendix 5. During the treatment phase and for at least 4 days after the last dose of study medication 
• Capable of giving signed informed consent which includes a commitment to comply with the 
requirements and restrictions listed in the informed consent form (ICF) and within this protocol. 
6.2 Exclusion Criteria  
Participants are excluded from the study if ANY of the following criteria apply: 
Exclusion Criteria: 
1) Patients who have previously had a score of 6 or 7 on the WHO 9 -point Ordinal Scale  
2) Patients who require support with invasive mechanical ventilation at the time of inclusion , or 
expected  to be required  within 24 hours of randomization 
 Protocol Version 2.0 
 Page 25 of 70 3) Alanine aminotransferase (ALT)  OR aspartate aminotransferase (AST) >2 × the upper limit 
of normal (ULN) OR Total Biliru bin >ULN. In patients with a documented  history of 
Gilbert’s Syndrome AND baseline total bilirubin elev ation consistent with an exacerbation of 
Gilbert’s  Syndrome (i.e. no other cause of total bilirubin elevation), subjects may enroll  if 
total bilirubin is <5x ULN . 
4) Diagnosis of liver cirrhosis, esophageal varices, ascites or hepatic encephalopathy  
5) Chronic liver diseases such as autoimmune hepatitis, primary biliary cholangitis, primary 
sclerosing cholangitis, Wilson’s disease, haemochromatosis  
6) Significant renal disease or infection (as determined by the Investigator) including stage 4 
chronic kidney disease or estimated glomerular filtration rate <60mL/min   
7) Absolute neutrophil count ≤1000/µL at screening  
8) Myocardial infarction, transient ischemic attack or stroke within 3 months prior to the first 
dose 
9) Current u nstable angina or congestive heart failure (New York Heart Association III/IV) 
10) Screening 12- lead E KG with a measurable QTc interval according to Fridericia correction 
(QTcF) >450 ms 
11) Anticipated transfer to another hospital that is not the study center within 24 hours 
12) Allergy to study medication or excipients 
13) Inability to swallow tablets  
14) Other documented comorbidities or laboratory abnormalities that in the opinion of the Investigator could affect the outcome of the study assessments, participant safety, or ability of the participant to comply with the requirements of the protocol 
15) Any patient whose interests are not best served by study participation, as determined by the Investigator 
Excluded Prior/Concomitant Therapy  
16) Requirement for medications mainly metabolized by CYP2C9 and with narrow therapeutic index (eg, warfarin, phenytoin) is prohibited unless therapeutic monitoring available for duration of alvelestat dosing  
17) Medicines that are potent CYP3A4 inhibitors including (but are not limited to) clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, ritonavir, verapamil and potent inducers including but not limited to phenobarbital, phenytoin and rifampicin, will be exclusionary 
18) Requirement for medications substantially reliant on OATP1B1 for metabolism where discontinuation during study drug administration is not possible or where fluctuations in 
levels are considered clinically important (as per investigat or judgement) and cannot be 
clinically monitored (e.g., statins, valsartan, olmesartan, enalapril, repaglinide) 
 Protocol Version 2.0 
 Page 26 of 70 Excluded Prior/Concurrent Clinical Study Experience  
19) Participation in any clinical investigation using investigational treatments within 4 weeks or 
5 half-lives of the drug (whichever is longer) prior to the initial dosing (or longer if required 
by local regulations) is prohibited. Use of remdesivir (Veklury) or other COVID -19 
therapies, including antibody treatment under the conditions of the auth orization  for 
emergency use in the US , and per manufacturer’s  instructions, is permitted . 
6.3 Lifestyle Restrictions  
6.3.1 Meals and Dietary Restrictions  
There are no specific restrictions in respect of mealtimes and administration of study treatment. 
6.3.2 Alcohol and Tobacco 
Participants should avoid alcohol during the 5 or 10  days of study drug dosing. 
6.3.3 Activity  
Subjects should not participate in unaccustomed or more vigorous exercise than usual routine in 
the 48 hours before each blood sample for laboratory safety tests.  
6.4 Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are not subsequently random ized. A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, available eligibility 
criteria, and any SAE s.  Individuals who do not meet the criteria for participation in this study 
(screen failures) may be rescreened  after discussion with and approval of the Principal  
Investigator (PI) . 
Additionally , individual laboratory  parameters or screening test s may be repeated , within the 
screening period, if the result is considered aberrant or not clinically consistent with the patient’s health status. Decisions to re-test should be made in conjunction with the study PI. 
7.0 TREATMENTS 
Study treatment is defined as the investigational treatment alvelestat (MPH966).   
 Protocol Version 2.0 
 Page 27 of 70 7.1 Treatment s Administered  
There are no bioavailability data to support administration of alvelestat given dissolved in fluid 
or as broken/crushed tablets for administration via nasogastric or other enteric feeding tube. If 
participants are unable to swallow tablets orally , study drug treatment needs to be discontinued 
(Section 8.1). 
Study Treatment Name:  30mg a lvelestat tablets  Placebo  
Dosage Formulation:  Tablet  Tablet  
(identical in appearance to active)  
Unit Dose Strength(s) / Dosage 
Level(s):  Days 1-5 (or 10) : 240mg bid  
(8 x 30mg tablets bid)  Days 1-5 (or 10) :  8 x tablets bid  
Route of Administration  Oral Oral 
Dosing Instructions:  To be taken bid, 12 hours apart  
Packaging and Labeling : Study treatment will be provided in wallets  and will be labeled as 
required per U.S. regulations. 
Manufacturer:  Mereo BioPharma 4 Ltd., 1 Cavendish Place, London, W1G 0QF, UK 
 
7.2 Method of Treatment Assignment  
All participants will be random ized via a random allocation to alvelestat or placebo arms to meet 
enrolment needs of the study. The randomization numbers will be linked to the 2 treatment 
regimens , and the randomiz ation scheme will not be stratified  
7.3 Blinding   
The placebo and alvelestat tablets are indistinguishable. This is double-blind study. The sponsor and principal investigator, will remain blinded to the study treatment allocation until the primary 
safety and efficacy assessment (based on Day 60 data). The site study team and participants will 
remain blinded until end of the study. The randomization list will be kept secure from the study team, Investigators, and participants throughout the conduct of the study and until unblinding is authoriz ed by the PI.  
7.4 Preparation/Handling/Storage/Accountability 
Only participant s enrolled in the study may receive study treatment, and only author ized site 
staff may supply or administer study treatment. All study treatments must be stored in a secure, 
 Protocol Version 2.0 
 Page 28 of 70 environmentally controlled, and monitored (manual or automated) area in accordance with the 
labelled  storage conditions with access limited to the Investigator and author ized site staff . 
The Investigator , institution, or the head of the medical institution  (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation , and final disposition records). 
Further guidance and information for the final disposition of unused study treatment are provided 
in the Manual of Procedures (MOP) . 
 
7.5 Treatment Compliance   
The per -protocol dosage, timing, and mode of administration of study treatment may not be 
changed  apart from dose titration to manage toleration . Any departures from the intended 
regimen must be recorded in the CRF  
7.6 Concomitant Therapy 
Treatment for COVID -19 disease, complications and co- morbidities  
Treatment required for medical management of COVID -19 and co- morbidities is allowed  
throughout the study, apart from protocol defined prohibited medications. Other i nvestigational 
treatments should not be started during the period of study follow up. 
CYP2C9 Substrates  
Alvelestat has a weak potential to inhibit CYP2C9. Therefore,  medications that are metabolized  
mainly by CYP2C9 and have a narrow therapeutic index are prohibited unless regular blood monitoring can be provided. Narrow therapeutic index CYP2C9 substrates include warfarin and phenytoin ( a complete list is included in the MOP  or online at 
http://medicine.iupui.edu/clinpharm/ddis/main -table ). 
Enhanced clinical monitoring in patients receiving sensitive/moderate sensitive CYP2C9 for enhanced clinical effect should be considered. Moderate sensitive substrates include tolbutamide  
and glimepiride.  
7.7 Treatment After the End of the Study   
Alvelesta t will not be provided a fter the end of the study.  
 Protocol Version 2.0 
 Page 29 of 70 8.0 DISCONTINUATION CRITERIA  
8.1 Discontinuation of Study Treatment   
In considering discontinuation of the study treatment, the Investigator should give particular 
consideration of the following: 
Liver Test Abnormalities  
The following monitoring schedule is proposed when a case of acute liver function abnormalities 
or worsening of a liver function abnormality is reported: 
1) If ALT or  AST increases to  >3 × ULN but < 5x ULN , in participants with normal 
transaminases at baseline, repeat testing within 48 to 72 hours including ALT, AST, ALP and 
Total Bilirubin  [TB], should be performed and query for symptoms made. If repeat testing 
shows ALT or AST persists >3 x ULN (alternatively  2-fold increase above baseline for 
participants with abnormal values before study drug exposure), close observation is to be 
initiated as follows: 
• Regular monitoring (twice to three times  a week) is required (AST, ALT, ALP and TB)  
• Initiate potential DILI evaluation for alternative etiologies . Testing for alternative 
etiologies can include serology tests (hepatitis A, hepatitis B, hepatitis C, 
Cytomegalovirus (CMV), Epstein- Barr Virus (EBV), Herpes Simplex Virus (HSV), 
varicella zoster virus (VZV), parvovirus, toxoplasmosis), imaging, and pathology assessments (creatine phosphokinase, clotting) as appropriate to the clinical situation. Consider a hepatology consult.  
• Follow the patient , if laboratory parameters stabilize or normalize the patient can 
continue on study treatment during this period.   
If the increase in ALT or AST to > 3 x ULN is also in association  with abnormalities in TB 
or INR or with clinical hepatitis  as specified below , study drug MUST  be stopped. 
 
2) If AST or ALT are ≥5x ULN, a repeat value should be obtained within 24-48 hours. If the repeat ALT OR AST values is ≥5 x ULN, the drug should be discontinued and the patient 
followed until the laboratory values normalize or stabilize, in addition to initiating potential (Drug Induced Liver Injury) DILI evaluation. 
3) When the following abnormal liver test conditions are met, study treatment MUST  be 
discontinued, th e study PI b e informed , and further steps discussed: 
• ALT or AST >3  × ULN and total bilirubin >2 × ULN OR 
• ALT or AST >3  × ULN and  international normal ized ratio  (INR) >1.5 OR   
 Protocol Version 2.0 
 Page 30 of 70 • Any elevation in ALT or AST with  clinical hepatitis: ALT or AST >ULN and the 
appearance of worsening fatigue, nausea, vomiting, right upper quadrant pain/tenderness, 
fever, rash , or eosinophilia  
• Alkaline phosphatase >2x ULN and direct bilirubin >2 x ULN 
4) When the following hepatic adverse events are met, study treatment MUST  be discontinued, 
the study PI be informed, and further steps discussed: 
• Regardless of the magnitude of the transaminase elevation, if the bilirubin is elevated 
(any level) in addition to the presence of signs and symptom(s) such as rash, eosinophilia, nausea, vomiting, or right upper quadrant pain 
• INR ≥1.5 (unless due to therapeutic anti-coagulant use) and TB ≥2.5 x ULN, irrespective of the magnitude of ALT or AST elevation 
• TB elevation ≥2.5 x ULN, and ALP ≥2.5 x ULN for cholestatic liver injury.  
For each scenario, initiate potential DILI evaluation for alternative etiologies and consider a hepatology consult. Liver biopsy should be considered for DILI. The complete liver profile including PT/INR must be repeated within 48-72 hours after first abnormal value is obtained. Follow the patient until laboratory parameters stabilize or normalize. Study medication can be restarted only if an alternative etiology is “definitively” identified and liver tests have returned to baselin e. Testing for alternative etiologies can include serology tests (hepatitis A, hepatitis B, 
hepatitis C, Cytomegalovirus (CMV), Epstein- Barr Virus (EBV), Herpes Simplex Virus (HSV), 
varicella zoster virus (VZV), parvovirus, toxoplasmosis), imaging, and pathology assessments (creatine phosphokinase, clotting) as appropriate to the clinical situation.  
Clinically significant liver function abnormalities should be reported as an AE/AESI. 
EKG Abnormalities  
If a clinically significant finding is identified (including but not limited to changes from baseline 
in QTcF  after enrolment), the Investigator or qualified designee will determine if the participant 
can continue in the study and if any change in participant management is needed. This review of the E KG printed at the time of collection must be documented. Any new clinically relevant 
finding should be reported as an AE. 
When the following EK G change conditions are met, study treatment MUST  be discontinued, 
the study PI informed , and further steps discussed: 
• Absolute QTcF >500 ms or >60 ms increase from baseline as confirmed with 3 consecutive 
EKGs taken in a 30- minute period with at least 5 min utes between each E KG. The mean of 
the 3 EK Gs will be used for decision making. 
 Protocol Version 2.0 
 Page 31 of 70 Acute Kidney  Injury (AKI) 
Alvelestat is predominantly renally excreted and the effect of acute kidney failure on PK is 
unknown. Participants who develop AKI requiring dialysis or hemofiltration must have study 
drug discontinued. 
Other Laboratory Parameters  
Study treatment MUST  be d iscontinued if the following laboratory parameters criteria are met: 
• Absolute neutrophil count less than or equal to 0.5 x 109/L on 2 consecutive repeat tests  
within 48 to 72 hours. 
Other 
Study treatment MUST  be discontinued if the following other criteria are met:  
• Significant safety issues (as judged by the Investigator). This includes AEs considered 
unacceptable by the patient and/or the Investigator 
• Any other protocol deviation that results in a significant risk to subject’s safety 
• Pregnancy as confirmed  by positive urine test at any time during the study 
• Withdrawal of informed consent. 
• Progression to intubation/mechanical ventilation or other  circumstance where continued 
administration of study drug tablets by the oral route is not possible. 
Participants  may volunt arily discontinue inve stigational treatme nt for any r eason at an y time. 
Participant decision  on discontinua tion of study treatment does not imply an automa tic 
withd rawal from the study.  
Refer to the Schedule of Assessments (SoA) for data to be collected at the time of treatment 
discontinuation (EoT) and follow-up and for any further evaluations that need to be completed . 
8.1.1 Temporary Discontinuation  
Study treatment dosing may be temporarily suspended in the event of: 
• Clinically important laboratory abnormalities  
• Other intercurrent illnesses  including acute new infection, major surgery , or gastrointestinal 
problems 
• Use of prohibited treatment 
• Any other protocol deviation that results in a significant risk to the participant’s safety . 
 Protocol Version 2.0 
 Page 32 of 70 After a laboratory abnormality leading to a delay of dosing normalizes sufficiently, study 
treatment may resume at the discretion of the Investigator in consultation with th e PI as needed . 
Similarly, study treatment may resume after the medication leading to suspension of dosing is discontinued. A decision to discontinue study treatment and/or to reinstitute study treatment should be conveyed to the Study PI. The Investigator may suspend study treatment at any time, without consultation with the Study PI if the urgency of the situation requires immediate action 
and if this is determined to be in the participant’s best interest. However, the Study PI should be 
contacted as soon  as possible in any case of study treatment discontinuation. 
8.1.2 Dose D e-escalation due to Study Drug Intolerance  
If a participant is unable to tolerate study drug at any time during the study due to symptoms of headache, nausea or vomiting despite use of appropriate symptomatic or prophylactic treatments, the study drug dose may be reduced for the remainder of the treatment period. This may only occur  if the following criteria are met and the event is considered related to study drug as 
assessed by the investigator : 
• Adverse event of headache meeting Common Terminology Criteria for Adverse Events of > 
Grade 3 (Severe pain; limiting self -care activities of daily living) . 
And/or 
• Adverse event of nausea meeting Common Terminology Criteria for Adverse Event of > 
Grade 3 (inadequate oral caloric or fluid intake). 
And/or 
• Adverse event of vomiting meeting Common Terminology Criteria for Adverse Event of > 
Grade 3 (requiring IV hydration or other medical intervention). 
The change needs to be recorded in the CRF . 
Refer to Appendix 7 for further details of Common Terminology Criteria for Adverse Events 
(CTCAE).  
8.1.3 Re-challenge  
Resumption of study treatment after temporary discontinuation should always be discussed with the study PI or delegate. 
Re-challenge should be performed one time only  if the study medication was held due to AST or 
ALT ≥ 5x ULN. Re-challenge should only occur after the A LT or AST return to pretreatment 
baseline value AND where there is a documented rationale that the elevation was not due to liver 
damage (e.g. technical error in blood test not compatible  with the clinical picture  and not present 
 Protocol Version 2.0 
 Page 33 of 70 on repeat testing , raised transaminase from  muscle source supported by creatine phosphokinase 
results) . 
In the specific case of liver tests meeting the study treatment disc ontinuation criteria in 
Section  8.1, no re- challenge is permitted.  
8.2 Discontinuation f rom the Study  
The Investigator should consider the following when withdrawing a participant from the study: 
• A participant may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioral, or 
administrative reasons . If a participant withdraws from study drug for any reason, they may 
remain  within the study if they continue to consent to do so. 
• If the participant  withdraws consent for disclosure of future information, UAB  may retain 
and continue to use any data collected before such the withdrawal of consent. 
• If a participant withdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the Investigator must document this in the site study records. 
8.3 Lost to Follow-up 
A participant  will be considered lost to follow -up if he/ she repeatedly fail s to return for 
scheduled visits and is unable to be contacted by the study site.  The following actions must be taken if  a participant fails to return to the clinic for a required 
study visit: • The site must attempt to contact the participant and reschedule the m issed visit as soon as 
possible and counsel the participant  on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant  wishes to and/or should continue in the 
study. 
• In cases in which the participant  is deemed lost to follow -up, the Investigator or designee 
must make every effort to regain contact with the participant  (where possible, 3 telephone 
calls and  mail a certified letter to the participant ’s last known mailing address. These contact 
attempts should be documented in the participant ’s file. 
• Should the participan t continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to f ollow-up. 
 Protocol Version 2.0 
 Page 34 of 70 9.0 STUDY ASSESSMENTS AND PROCEDURES  
• Study procedures and their timing are summar ized in the SoA.   
• Adherence to the study desig n requirements, including those specified in the SoA, is essential 
and required for study conduct. 
• All screening evaluations must be completed and reviewed to confirm that  potential 
participant s meet all eligibility criteria. The Investigator will maintain a screening log to record 
details of all participant s screened and to confirm eligibility or record reasons for screening 
failure, as applicable.  
• Sample handling: Routine bloodwork and laboratory measurements used for safety 
monitoring and eligibility assessment (CMP, coagulation measurements, CBC, pregnancy testing, etc. ) will be processed and measured using local laboratory.  Samples (blood) used 
for PK or biomarker assessment will undergo i nitial processing at the local site but will be 
shipped to a central lab (Dr. Wells) at UAB for curation and analysis.  The procedure is detailed in the MOP . 
• Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the samples . 
• Biomarker  samples (blood) will be stored for up to 60 months after the end o f the study.  
9.1 Key Screening Assessments  
• SARS -CoV-2 PCR testing  or SARS -CoV-2 antigen testing (routine diagnostic test used for 
diagnosis of current illness to be used, no additional test required). It is recognized  this may 
have been performed in the period prior to the screening period. 
• Laboratory testing performed for clinical management may be used for screening assessment 
if obtained with in 3 days of planned randomization. 
• EKG performed for clinical management may be used for screening assessment if obtained within 7 days of planned randomization. 
9.2 Efficacy Assessments  
9.2.1 Blood Biomarkers  
Blood 
Blood will be collected as per the S oA, and samples will be collected and processed as described 
by the MOP . Samples may be stored for a maximum of 60 months following the end of study at 
a facility selected by the investigators to enable further analysis of biomarker responses to 
alvelestat .  
Blood Biomarkers of Efficacy Collected  
• NETosis  
o cell-free DNA 
o citrullinated histone H3  
o Myeloperoxidase (MPO) -DNA complexes)  
 Protocol Version 2.0 
 Page 35 of 70 • Neutrophil Elastase  
o Plasma de smosine/isodesmos ine 
• Inflammation  
o Absolute and percentage neutrophil count 
o Absolute and percentage lymphocyte count 
o Neutrophil-lymphocyte ratio [NLR] derived 
o C-Reactive protein  
o IL-1beta 
o IL-6 
o IL-8 
o TNF -alpha) 
o Procalcitonin  
• Coagulopathy  
o D-dimer  
In addition, samples will be stored and analysis may  be performed on additional biomarker 
variants thought to play a role in neutrophil elastase–induced damage to evaluate their 
association with observed neutrophil activation responses to alvelestat.  
9.2.2 SaO 2/FiO 2 (Oxygen saturation/fraction inspired oxygen 
The ratio of O 2 saturation to fraction inspired O 2 (SaO 2/FiO 2) is a reliable, non -invasive 
surrogate for PaO2/FiO 2 and predictive for 3-day worsening in pat ients with COVID-19 
infection  (Vultaggio et al 2020). This will be collected  at baseline and during the study as in the 
SoA, measured  as per local standard operating procedures.  
9.3 Clinical Outcome Efficacy  Measure ments  
The following information  will be  recorded  for the Clinical Efficacy Endpoint Assessments, 
including those in 9.3.1 and  9.3.2: 
• Date of hospitalization and discharge 
• Dates of admission to and discharge from ICU 
• Date of death  
• Daily respiratory support requirements (room air, oxygen by mask or prongs, high flow oxygen, non-invasive ventilation, Extracorporeal Membrane Oxygenation (ECMO), invasive mechanical ventilation  (to complete the Disease Progression Endpoint Assessment)) 
• Organ support, vasopressors, renal replacement 
• Limitation of activities  of daily living (as required for the WHO 9-point ordinal scale) 
 Protocol Version 2.0 
 Page 36 of 70 9.3.1 Effect on disease progression recorded as participant status  
• Alive and free of respiratory failure 
• Alive with respiratory failure (need for high- flow oxygen, Extracorporeal Membrane 
Oxygenation (ECMO), non-invasive or invasive mechanical ventilation 
9.3.2 WHO 9 -Point Ordinal Scale  
Each assessment will be recorded as a number in the CRF based on the status categories below. 
Where possible the timing of each assessment should be similar (i.e. morning or evening throughout) 
0. Uninfected, no clinical or virological evidence of infection 
1. Ambulatory, no limitation of activities 
2. Ambulatory, limitation of activities  
3. Hospitalized – mild disease, no oxygen therapy 
4. Hospitalized – mild disease, oxygen by mask or nasal prongs 
5. Hospitalized – severe disease, noninvasive ventilation or high flow oxygen 
6. Hospitalized – severe disease, intubation and mechanical vent ilation  
7. Hospitalized – severe disease, ventilation and additional organ support – vasopressors, renal 
replacement therapy, extracorporeal membrane oxygenation  
8. Death 
9.4 Safety Assessments 
Planned time points for all safety assessments are provided in the SoA. Daily safety and adverse 
event assessments may include data acquired from  routine clin ical care. SAEs only to be 
collected during screening. SAEs/AEs to be collected from Randomization to Day 60. 
9.4.1 Physical Examinations 
• A complete physic al examination will include, at a minimum, assessments of the 
cardiovascular, respiratory, gastrointestinal,  integumentary, and neurological systems. Height 
and weight will also be measured and recorded if possible, based on the clinical conditions. 
• A brie f physical examination will include, at a minimum, assessments of the lungs, heart, 
abdomen, and skin. 
• Investigators should pay special attention to clinical signs related to COVID -19 disease. 
 Protocol Version 2.0 
 Page 37 of 70 9.4.2 Vital Signs  
Vital signs will be measured in a semi-supine position after 5 minutes of rest and will include 
temperature, systolic and diastolic blood pressure, heart rate, respiratory rate, and pulse oximetry .  
• Oral or tympanic temperature . 
• Blood pressure and pulse measurements will be assessed with a completely automated device. Manual techniques will be used only if an automated device is not available. 
• Blood pressure and pulse measurements should be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e .g., television, cell phones). 
Electrocardiograms  
• 12-lead E KG will be obtained as outlined in the SoA using an EK G machine that 
automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals  where 
possible . Refer to Section  8.1 for QTc withdrawal criteria and additional QTc readings that 
may be necessary.  
• Single EK Gs will be performed at all scheduled time  points, with the exception of when a 
change from baseline occurs that meets drug discontinuation criteria ( Section  8.1). In this 
situation , a triplicate measurement is required to confirm the finding and for discontinuation 
decisions. 
• When a triplicate E KG is required, 3 consecutive EK G tracings should be taken in a 30-
minute period with at least 5 minutes between each E KG. 
• QTc value will be calculated using the Fridericia formula (QTc=QT/3√RR) . Alternative may 
be used in discussion with PI. 
9.4.3 Headache 
A proactive query for headache will be made at Baseline, and at end of treatment as per SoA and graded by CTCAE criteria (Grade 0 - No headache, Grade 1 Mild pain Grade 2 -Moderate pain; 
limiting instrumental activities of daily living, Grade 3 Severe pain; limiting self -care activities 
of daily living). 
9.4.4 Clinical Safety Laboratory Assessments 
• Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the S OA 
for the timing and frequency. 
• The Investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF. The 
laboratory reports must be filed with the source documents. Clinically significant abnormal laboratory findings are those that are not associated with the underlying disease, unless 
judged by the Investigator to be more severe than expected for the participant's condition. 
 Protocol Version 2.0 
 Page 38 of 70 • All laboratory tests with values considered clinically significantly abnormal during 
participation in the study should be repeated until the values return to normal or baseline, with a frequency based on the judgement of the Investigator. If such values do not return to normal/baseline within a period of time judged reasonable by the Investigator, the etiology should be identified and recorded in the CRF. 
The monitoring schedule proposed for a case of acute li ver function abnormalities or 
worsening of a liver function abnormality is reported is listed in Section  8.1 (Liver Test 
Abnormalities).  
• Clinically significant liver function abnormalities should be reported as an AE/AESI.  
• All protocol-required laboratory assessments, as defined in Appendix 2, must be conducted 
in accordance with the S OA.  
9.4.5 Data Monitoring  
Safety will be regularly reviewed by the Principal Investigator  or delegate. 
9.5 Adverse Events  
The definitions  of an AE, SAE, SUSAR, and UP can be found in Appendix 4. 
An AE  will be reported by the participant  (or, when appropriate, by a caregiver, surrogate, or the 
participant 's legally author ized representative) .  
The Investigator  and any  designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE and remain responsible for following AE s that 
are serious, considered related to the study treatment or the study, or that caused the participant  
to discontinue the study treatment (s ee Section  8.1). 
9.5.1 Time Period and Frequency for Collecting AE and SAE Information  
All SAE s will be collected from the signing of the ICF until the follow -up visit at the time  points 
specified in the SoA. SAEs/ AEs will be collected from Baseline/Randomization  to Day 60 and 
mortality to Day 90 . 
All SAE s will be recorded and reported to s afety reporting group within 24 hours, as indicated in 
Appendix 4.  
The method of recording, evaluating , and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 4. 
9.5.2 Follow- up of an AE and /or SAE  
After the initial AE/SAE report, the Investigator is required to proactively follow each 
participant  at subsequent visits/contacts. All SAE s and non-serious AESIs (as defined in  
 Protocol Version 2.0 
 Page 39 of 70 Section  9.5.3), will be followed until resolution, until stabiliz ation, until the event is otherwise 
explained, or until the participant is lost to follow -up (as defined in Section  8.3). Further 
information on follow-up procedures is given in Appendix 4. 
9.5.3 Adverse Events of Special Interest  
Some AEs, regardless of their severity or outcome, will be expedited due to the relevance for 
subject safety or study treatment safety profile. These events should be reported to safety 
reporting group within 24 hours, as indicated in Appendix 4 . The AESIs for alvelestat are:  
• Liver function a bnormalities  defined as:  
a) Any occurrence of (i) ALT or AST elevations >5  × ULN or (ii) ALT or AST >3  × ULN 
and total bilirubin >2 × ULN or INR  >1.5 or the appearance of worsening fatigue, 
nausea, vomiting, RUQ pain/tenderness, fever, rash, or eosinophilia. 
b) Any occurrence of <5 × ULN or ALT or AST <3  × ULN and total bilirubin <2 × ULN 
where the tests have been repeated  within 48 to 72 hours and the elevation confirmed on 
at least 2 separate occasions.  
For participant safety and to ensure that the hepatotoxic potential of the study treatment to be 
determined, a standardized  procedure for identification, monitoring, and evaluation of liver 
events must be followed as outlined in Section  9.4.4 and Section  8.1.  
• EKG 
If a study subject experiences any of the following cardiovascular events, the event should be reported immediately as an AESI and the study treatment discontinued: 
a) Absolute QTcF >500 ms or >60 ms increase from baseline. 
b) Any clinically significant cardiac  abnormality on EKG. 
• Infection  
Any new infection that requires the use of systemic antimicrobial treatment (antibiotics, anti-viral, anti-fungal, or anti -mycobacterial) should be investigated with clinically relevant 
diagnostic tests.  
• Neutropenia 
Absolute neutrophil count less than or equal to 500 per µL on 2 consecutive repeat tests  
within 48 to 72 hours.  
 Protocol Version 2.0 
 Page 40 of 70 9.5.4 Regulatory Reporting Requirements for SAE  
• Prompt notification by the Investigator to safety reporting group of an SAE is essential so 
that legal obligations and ethical responsibilities towards the safety of participant s and the 
safety of a study treatment under clinical inves tigation are met.  
• Mereo  have a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies  about the safety of a study treatment under clinical investigation.  
• Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions  (SUSARs) according to local regulatory requirements and will be  forwarded to 
Investigator s as necessary.  
• An Investigator who receives an Investigator safety report describing an SAE or other 
specific safety in formation ( e.g. summary or listing of SAEs ) will file it along with the 
Investigator’s Brochure and will notify the IRB/IEC, if appropriate according to local requirements . 
9.5.5 Pregnancy  
• Details of all pregnancies in female participant s and female partners of male participant s will 
be collected after the start of study treatment and until 5 half-lives (4 days) after the last dose. 
• If a pregnancy is reported, the Investigator should inform the safety reporting group within 
24 hours of learning of the pregnancy and should follow the procedures outlined in Appendix 5. 
• Abnormal pregnancy outcomes (e.g. spontaneous abortion, fetal death, stillbirth, congenital anoma lies, ectopic pregnancy) are considered SAE s. 
Partner Pregnancies  
Pregnancy outcomes must be collected for the female partners of the subjects who took study treatment in this study. Pregnancy itself is not regarded as an AE unless there is suspicion that the study treatment may have interfered with the effectiveness of a contraceptive medication. If a 
pregnancy is reported for a subject’s partner, study treatment will be immediately discontinued. The outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth, or congenital abnormality) must be followed and documented. A f ollow-up report should be sent 
with any new information regarding the pregnancy and the outcome of the birth.  
9.6 Treatment of Overdose  
For this study, any dose of a lvelestat greater than 240 mg  bid within a 24-hour time period w ill 
be considered an overdose. 
There is no specific treatment for an overdose. Any t reatment should be supportive as indicated 
by the subject's condition. 
 Protocol Version 2.0 
 Page 41 of 70 In the event of an overdose, the Investigator/treating physician should: 
1) Contact the study PI immediately . 
2) Closely monitor the participant  for AE/SAE  and laboratory abnormalities until alvelestat  can 
no longer be detected systemically (at least  3 days). 
3) Obtain a plasma sample for PK analysis within 3 days from the date of the last dose of study 
treatment if requested by the study PI (determined on a case -by-case basis) . 
4) Document the quantity of the excess dose as well as the duration of the overdosing in the 
CRF.  
Decisions regarding dose interruptions or modifications will be made by the Investigator in consultation with  the Study PI as necessary based on the clinical evaluation of the participant . 
9.7 Pharmacokinetics  
Sparse PK sampling will be performed before  and after study treatment dosing as detailed in the 
SoA and Study Manual. 
• Blood samples of approximately 3 mL will be collected for measurement of blood 
concentrations of alvelestat  as specified in the SoA. Instructions for the collection and 
handling of biological samples  are in the MOP . The actual date and time (24 -hour clock 
time) of each sample will be recorded . 
9.8 Pharmacodynamics  
Pharmacodynamic markers form the secondary efficacy endpoints in this study and are covered 
in Section  9.2.1. 
10.0 STATISTICAL CONSIDERATIONS  
10.1 Sample Size Determination   
Over the course of the study, 15 participants will be randomized in a 2:1 ratio to receive one of 
the following:  alvelestat or placebo  on top of SoC or SoC alone .  
The primary objective of the study is safety and tolerability. All efficacy analyses are considered 
exploratory and hypothesis-generating. This is a pilot study and it is not formally powered based on any specific endpoint. Sample size has been set to minimize the number of patients exposed, but still large enough to give adequate safety and tolerability data to support progression of further development, to support estimates on the PK of alvelestat in the target population  and to 
examine for signals on mechanist ic and clinical outcome effect.  
 Protocol Version 2.0 
 Page 42 of 70 10.2 Populations for Analyses 
For purposes of analysis, the following populations are defined: 
Population Description  
Enrolled Set  The Enrolled S et will include all participants who sign the ICF  
Full Analysis  Set The Full Analysis S et will include all subjects who signed the ICF  and 
were subsequently random ized into the study. Subjects will be analy zed 
according to randomized treatment (alvelestat or placebo) . The  FAS will 
be used for efficacy analyses.  
Safety Set  All randomized participants who take at least 1 dose of study drug.  
Participants will be analyzed  according to randomized treatment. The 
Safety Set will serve as the primary population for the analysis of safety 
and tolerability primary endpoint. Subjects will be analyzed according to randomized treatment (alvelestat or placebo)
 
Per-Protocol Set Used for sensitivity testing and signal detection for efficacy analyses . The 
Per-Protocol Set includes all participants from the Full Analysis Set who 
have been treated according to the protocol and fulfil the following criteria:  
1) All inclusion/exclusion criteria affecting efficacy satisfied  
2) Absence of relevant protocol violations with respect to factors 
likely to affect the efficacy of  alvelestat treatment . 
3) Adequate alvelestat  compliance  
Subjects will be analyzed  according to random ized treatment.
 
PK Set  The PK Set will include all participants randomized to the alvele stat arm 
in the S afety Set who have at least 1 evaluable serum concentration.  
 
10.3 Statistical Analyses  
The main population for safety and tolerability analysis will be the Safety Set. The main 
population for efficacy analysis will be the Full Analysis Set; supportive analyses will also be 
performed using the Per -Protocol Set.  
Continuous data will be presented using descriptive summaries (e .g., mean, standard deviation, 
minimum, maximum, median, lower quartile , and upper quartile) . Categorical variables wi ll be 
presented by the number of observations and relative (%) frequency.   
Unless otherwise stated, baseline value for any variable will be the last value taken prior to the 
first dose of study medication. 
 Protocol Version 2.0 
 Page 43 of 70 Unless otherwise stated, all statistical tests will be 2 -sided and conducted at the 5% level. All 
presented confidence intervals will be 2 -sided 95% confidence intervals. 
Handling of Missing Data  
The study is designed to reduce the extent of missing data by alignment of assessments with 
routine clinical management where possible, by the use of clinical outcomes measures that are 
expected to be routinely collected for hospitalized patients with COVID -19 and use of telehealth 
assessments where appropriate to reduce the study b urden on patients. However, missing data 
must be anticipated and handled as follows: 
When a patient drops out of a trial full reporting of all reasons for their discontinuation will be 
collected.  
For statistical analy zes missing values are considered a potential source of bias. A multiple 
imputation of missing data approach will be applied, using pattern mixture model methodology. 
Within each treatment, 4 proposed data patterns will be defined as follows:  
• Pattern 1: will include patients who completed treatment on study drug 
• Pattern 2: will include patients who discontinue treatment early due to AEs 
• Pattern 3: will include patients who discontinue treatment early due to lack of therapeutic efficacy (LOTE)  
• Pattern 4: will include p atients who discontinue treatment early due to reasons other 
than AE event or LOTE. 
The strategy for dealing with missing values will be further detailed in the statistical analysis plan. If the pattern of missing data is different to that envisaged, inclu ding following blinded 
review of the data at the end of the trial the strategy and the Statistical Analy sis Plan (S AP) will 
be updated. 
Descriptive statistical summaries will use Observed Case (OC) data and no missing data values 
will be imputed.  
The SAP will be developed and final ized before  database lock and will describe the selection of 
participants to be included in the analyses and procedures for accounting for missing, unused, 
and spurious data. Below is a summary of planned statistical analyses of the primary and secondary endpoints. 
 Protocol Version 2.0 
 Page 44 of 70 10.3.1 Safety Analyses (Primary Endpoint)  
All safety analyses will be performed on the Safety Set . Comparison of alvelestat and placebo 
will be performed using an analysis of covariance (ANCOVA) model for continuous variables . 
Endpoint  Statistical Analysis Methods  
AEs will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). Summaries will be by system organ class and preferred term. Treatment -emergent AEs are defined as any AE occurring or worsening on or after 
the first dose of study medication. If a participant experiences the same preferred term multiple times , the event will be counted only once overall and by the greatest 
severity.  
The frequency and incidence of treatment -emergent AEs will be presented by 
system organ class and preferred term for each treatment group (number and 
percentage of participants experiencing at least 1 AE per preferred term as well as the number of observed events per preferred term). Separate tables will be presented by severity and by relationship. All AEs will be presented in full in a comprehensive listing including participant number, treatment regimen, severity, seriousness, action taken, outcome, relationship to treatment, onset/stop, and duration. Details of SAEs and AEs leading to withdrawal will be listed separately.  
Adverse Events of Special Interest  
AESIs,  including liver function abnormalities , EKG events , infections, and 
neutropenia, will be tabulated and summar ized by treatment group and overall. 
 Headache 
AE o f headache by CTCAE Grade will be summarized by the number and 
percentage within each category and change from baseline will be summarized by 
shift tables.  
Vital Signs  
Vital signs will be summar ized as observed values and change from baseline by 
treatment g roup and overall. 
Physical Examination 
Physical examination results will be listed by subject ID and body system. EKG EKG parameters will be summar ized as observed values and change from baseline 
by treatment group and study visit. Abnormal findings (“ norm al”, “abnormal, not clinically significant”, and 
“abnormal, clinically significant”) will be summar ized by the number and 
percentage within each category  and change from baseline will be summar ized by 
shift tables.  
Clinical Laboratory Laboratory parameters will be summarized  as observed values and change from 
baseline by treatment group and study visit. 
 Protocol Version 2.0 
 Page 45 of 70 Endpoint  Statistical Analysis Methods 
Values outside the normal range will be summar ized by the number and percentage 
within each category  and change from baseline will be summarized  by shift tables. 
Mortality  
The number and % of participants who have died by day 90. 
Safety and PK Relationships  
The safety correlation analysis with drug concentration may be done for the safety 
parameters shown to be sensitive to alvelestat exposure. The comparison of exposure will be done between groups with non- clinically significant changes and 
clinically significant changes in safety parameters using graphic and statistical methods where data allow.  
 
10.3.2 Efficacy Analyses (Secondary Endpoints) 
Comparison of alvelestat and placebo will be performed using an analysis of covariance 
(ANCOVA) model for continuous variables, with Least Squared means for the difference between pairwise treatment regimens, standard errors, two -sided 95% CIs and P- value for the 
difference between pairwise treatment regimens .  
Categorical variable will be compared between treatments by Chi-square test (or Fisher’s exact 
test as appropriate) . 
Endpoint  Statistical Analysis Methods 
Biomarkers Within individual absolute and % change from baseline will be 
calculated. An analysis of covariance (ANCOVA) model with baseline levels as a covariate and treatment strata as factors will be used to generate least squared means and least squared mean differences between treatment groups.  Continuous measures will be log transformed where appropriate.  
The parameters during treatment will be compared to the baseline 
values for active and placebo patients separately to evaluate natural variability of the markers.  
The time -matched biomarker values will be compared between 
placebo and active groups to assess the differences outside natural 
variability and time to significant change for the responsive biomarkers.  
SaO2/FiO 2 Within individual absolute and % change from baseline will be calculated.  
Disease progression   
(alive  and respiratory failure 
free) The proportion alive and respiratory failure free will be presented by the number of observations, absolute and relative (%) frequency . 
 Protocol Version 2.0 
 Page 46 of 70 Endpoint  Statistical Analysis Methods 
Other c linical outcomes  Continuous variables (e.g. duration of hospital/IC U stay) mean, 
standard deviation, minimum, maximum, median, lower quartile, 
and upper quartile). 
Change is level of respiratory support will be presented as shift 
tables . 
Time to event (e. g. time to room air, to death, to discharge), will be 
analysed using Kaplan-Meier methods, and quartiles for the median time to event will be presented together with their 95% confidence intervals. Comparisons between treatment regimens will be performed by means of the log- rank test.  
Disease severity   
(WHO 9 -point ordinal scale)  Change from baseline will be presented as mean, standard deviation, minimum, maximum, median, lower quartile, and upper quartile).  
Responder analyses (improvement and deterioration) will be presented as number of observations, absolute and relative (%) frequency . 
 
10.3.3 PK Analyses  
Descriptive PK analyses will be  provided and assessed within the existing Population PK model. 
10.3.4 Interim Analyses   
No interim analysis is planned for this study.   
 Protocol Version 2.0 
 Page 47 of 70 11.0 REFERENCES  
1. Argenziano, M., Bruce, S., Slater, C., et al. (2020) Characterization and clinical course of 
1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ, 369, p401. doi: 10.1136/bmj.m1996. 
2. Barnes, B.J., Adrover, J.M., Baxter-Stoltzfus, A. et al. (2020) Targeting potential drivers of COVID -19: Neutrophil extracellular traps. J Exp Med, 217(6). doi: 
10.1084/jem.20200652. 
3. Cao, B., Wang, Y., Wen, D. et al. (2020) A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med, 382(19), 1787-1799. doi: 10.1056/nejmoa2001282. 
4. Elborn, J.S., Perrett, J., Forsman-Semb, K. et al. (2012) Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. Eur Respir J, 40(4), 969-976. doi: 10.1183/09031936.00194611. 
5. Geleris, J., Sun, Y., Platt, J. et al. (2020) Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid -19. N Engl J Med, 382(25), 2411-2418. doi: 
10.1056/nejmoa2012410. 
6. Goyal, P., Choi, J.J., Pinheiro, L.C. et al. (2020) Clinical Characteristics of Covid-19 in New York City. N Engl J Med, 382(24), 2372-2374. doi: 10.1056/nejmc2010419. 
7. Grein, J., Ohmagari, N., Shin, D. et al. (2020) Compassionate Use of Remdesivir for Patients with Severe Covid -19. N Engl J Med, 382(24), 2327-2336. doi: 
10.1056/nejmoa2007016. 
8. Gunawardena, K., Gullstrand, H. & Perrett, J. (2013) Pharmacokinetics and safety of AZD9668, an oral neutrophil elastase inhibitor, in healthy volunteers and patients with COPD. Int J Clin Pharmacol Ther. 51(4), 288-304. doi: 10.5414/CP201674. 
9. Holshue, M.L., DeBolt, C., Lindquist, S. et al. (2020) First Case of 2019 Novel Coronavirus in the United States. N Engl J Med, 382(10), 929-936. doi: 10.1056/nejmoa2001191. 
10. Horby P, Lim WS, et al. (2020) Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med; 10.1056/NEJMoa2021436. doi:10.1056/NEJMoa2021436. 
11. Ingraham, N.E., Lotfi-Emran, S., Thielen, B.K. et al. (2020) Immunomodulation in COVID-19. Lancet Respir Med, 8(6), 544-546. doi: 10.1016/s2213-2600(20)30226-5. 
12. Iwata, K., Doi, A., Ohji, G. et al. (2010) Effect of Neutrophil Elastase Inhibitor (Sivelestat Sodium) in the Treatment of Acute Lung Injury (ALI) and Acute Respiratory 
Distress Syndrome (ARDS): A Systematic Review and Meta -Analysis. Intern Med, 
49(22), 2423-2432. doi: 10.2169/internalmedicine.49.4010. 
 Protocol Version 2.0 
 Page 48 of 70 13. Kim, E.H., Wong, S-W., & Martinez, J. (2019) Programmed Ne crosis and Disease:We 
interrupt your regular programming to bring you necroinflammation [sic]. Cell Death 
Differ, 26(1), 25 -40. doi: 10.1038/s41418-018-0179-3. 
14. Kuna, P., Jenkins, M., O’Brien, C.D. et al. (2012) AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir Med, 106(4), 531-539. doi: 10.1016/j.rmed.2011.10.020. 
15. Lewnard, J.A., Liu, V.X., Jackson, M.L. et al. (2020) Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. BMJ, p.m1923. doi: 10.1136/bmj.m1923. 
16. Li, H., Zhou, X., Tan, H. et al. (2018) Neutrophil extracellular traps contribute to the pathogenesis of acid- aspiration -induced ALI/ARDS. Oncotarget 9(2), 1772-1784. doi: 
10.18632/oncotarget.22744. 
17. McElvaney, O.J, McEvoy, N., McElvaney O.F. et al. (2020) Characterization of the Inflammatory Response to Severe COVID -19 Illness. AJRCCM Published June 25. 
doi: 10.1164/rccm.202005-1583OC. 
18. Mercuro, N.J., Yen, C.F., Shim, D.J. et al. (2020) Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID- 19). JAMA Ca rdiol. doi: 10.1001/jamacardio.2020.1834. 
19. Miyoshi, S., Ito, R., Katayama, H. et al. (2014) Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients. Drug Des Devel Ther, 1211. doi: 10.2147/dddt.s68030. 
20. Papayannopoulos, V., Metzler, K.D., Hakkim, A. et al. (2010) Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol, 191(3), 677-691. doi: 10.1083/jcb.201006052. 
21. Phipps MM, Barraza LH, LaSota PR, et al. (2 020) Liver Injury in COVID- 19: Prevalence 
and Association with Clinical Outcomes in a Large US Cohort. Hepatology 30 May. doi.org/10.1002/hep.31404. 
22. Pu, S., Wang, D., Liu, D. et al. (2017) Effect of sivelestat sodium in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis. BMC Pulm Med. 17:148. doi: 10.1186/s12890-017-0498- z. 
23. Stevens, T., Ekholm, K., Gränse, M., et al. (2011) AZD9668: Pharmacological Characterization of a Novel Oral Inhibitor of Neutrophil Elastase. J Pharmacol Exp Ther, 339(1), 313-320. doi: 10.1124/jpet.111.182139. 
24. Stockley, R., De Soyza, A., Gunawardena, K., et al. (2013) Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med, 107(4), 524-533. doi: 10.1016/j.rmed.2012.12.009. 
 Protocol Version 2.0 
 Page 49 of 70 25. Vultaggio, A., Vivarelli E., Virgili, G, et al (2020) Prompt predicting of early clinical 
deterioration of moderate- to-severe COVID -19 patients: usefulness of a combined score 
using IL-6 in a preliminary study (Pre- Proof) The Jo urnal of Allergy and Clinical 
Immunology: In Practice. June. doi: 10.1016/j.jaip.2020.06.013. 
26. World Health Organization | Coronavirus disease (COVID-19) Situation Report 142 (10 June 2020). Retrieved 24 June 2020, from https://www.who.int/docs/default-source/coronaviruse/situation -reports/20200610- covid -19-sitrep -142.pdf. 
27. Zhu, N., Zhang, D., Wang, W. et al. (2020) A Novel Coronavirus from Patients with 
Pneumonia in China, 2019. N Engl J Med, 382(8), 727-733. doi: 10.1056/nejmoa2001017. 
28. Zuo, Y., Yalavarthi, S., Shi, H. et al. (2020) Neutrophil extracellular traps in COVID-19. 
JCI Insight. 5(11), e138999. doi: 10.1172/jci. insight.138999. 
 
 Protocol Version 2.0 
 Page 50 of 70 12.0 APPENDICES  
APPENDIX 1:  ABBREVIATIONS, TRADEMARKS  & GLOSSARY  
Abbreviation  Description  
AAT  Alpha -1antitrypsin  
AATD  Alpha -1 antitrypsin deficiency  
AE Adverse event  
AESI  Adverse event of special interest  
ALT  Alanine aminotransferase  
ANCOVA  Analysis of covariance  
AST  Aspartate aminotransferase  
AUC  Area under the curve  
BAL  Bronchoalveolar lavage  
bid Twice (2 times) a day  
cf-DNA  cell-free DNA  
CFR  United States Code of Federal Regulations  
CMV  Cytomegalovirus  
COA  Clinical Outcome Assessment  
CONSORT  Consolidated Standards of Reporting Trials  
COPD  Chronic obstructive pulmonary disease  
COVID -19 Coronavirus disease 2019  
CRF  Case report form  
CT Computerized or computed tomography  
CTCAE  Common Terminology Criteria for Adverse Event  
CYP2C9  Cytochrome P450 2C9  
DAMPs  Damage Associated Molecular Pattern Molecules  
DILI  Drug Induced Liver Injury  
dL Decilit er 
EBV  Epstein -Barr virus  
EKG Electrocardiogram  
ECMO  Extracorporeal Membrane Oxygenation  
eCRF  Electronic case report form  
EoS End of Study  
EoT End of Treatment  
FAS  Final Analysis Set  
FEV1  Forced expiratory volume in 1 second  
FU Follow -up 
g Gram  
GCP  Good Clinical Practice  
h Hour  
hCG  Human chorionic gonadotropin  
HRT  Hormone replacement therapy  
 Protocol Version 2.0 
 Page 51 of 70 Abbreviation  Description  
HSV  Herpes simplex virus  
Hy’s Law  A rule of thumb that a patient is at high risk of a fatal drug -induced liver injury 
(DILI) if given a medication that causes hepatocellular injury (not cholestatic injury) 
with jaundice  
IC50  The concentration of an inhibitor where the response (or binding) is reduced by half  
ICF Informed consent form  
ICH  International Conference on Harmonization  
ICU Intensive Care Unit  
IL-1β Interleukin 1 beta  
IL-6 interleukin -6 
IL-8 interleukin -8 
IND Investigational new drug  
INR International normalized ratio  
IRB Institutional Review Board  
Ki Inhibitory constant  
kPa kiloPascal, a unit of force  
LOTE  Lack of therapeutic efficacy  
LTB4  Leukotriene b4  
MedDRA  Medical Dictionary for Regulatory Activities  
mg/dL  Milligrams per decilit er 
mIU  Milli International Units  
MOP  Methods of procedures  
MPO  Myeloperoxidase  
MS Millisecond  
NE Neutrophil elastase  
NET  Neutrophil extracellular trap  
NOAEL  No observed adverse effect level  
Pa Pascal  
PD Pharmacodynamics  
PI Principal investigator  
PK Pharmacokinetics  
PR time from the onset of the P wave to the start of the QRS complex on E KG 
QRS  Represents ventricular depolarization on E KG 
QT The duration of ventricular depolarization and repolarization on E KG 
QTc  Corrected QT inte rval 
QTcF  QTc by Fridericia’s correction method  
QTcV  QTc by Van de Water’s correction formula  
RANTES  Regulated on activation, normal T cell expressed and secreted  
RBC  Red blood cell  
SAE  Serious adverse event  
SaO 2/FiO 2 Ratio  oxygen saturation to fraction inspired oxygen  
SAP  Statistical Analysis Plan  
 Protocol Version 2.0 
 Page 52 of 70 Abbreviation  Description  
SARS -CoV -2 Severe Acute Respiratory Syndrome coronavirus -2 
SoA Schedule of Assessments  
SoC Standard of Care  
SOP  Standard operating procedure  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
TB Total bilirubin  
TEAE  Treatment emergent adverse event  
ug Microgram  
ULN  Upper limit of normal  
uM Micromolar  
UPs Unanticipated problems  
VZV  Varicella zoster virus  
WBC  White blood cell  
  
 Pr ot oc ol Versi o n 2. 0 
 P a ge 5 3  of 7 0  A P P E N DI X  2:  C LI NI C A L L A B O R A T O R Y T E S T S  
• T he tests detaile d i n t he t a ble bel o w  will be perf or me d b y t he l ocal la b or at or y.  
• Pr ot oc ol-s pecific r e q uire me nts f or i ncl usi o n or e x cl usi o n of partici pa nts ar e detaile d i n 
Secti o n  6. 1  or Secti o n  6. 2 , res pecti vel y . 
• A d diti o nal tests ma y be perf or me d at a n y ti me d uri n g t he st u d y as deter mi ne d necessar y b y 
t he I n v esti gat or or r e q uir e d b y l ocal re g ul ati o ns. 
Pr ot oc ol- R e q uire d S a fet y a n d Effic ac y L a b or at or y Assess m e nts 
L a b or at or y 
Assess me nts  P ar a meters  
He mat ol o g y  Platelet C o u nt  
R B C C o u nt  
He m o gl o bi n  Mea n Cell Vol u me  
Mea n Cell 
He m o gl o bi n  W B C c o u nt wit h 
differe ntial ( % a n d 
a bs ol ute c o u nts): 
Ne utr o p hils 
L y m p h oc ytes 
M o n oc ytes 
E osi n o p hils 
Bas o p hil s I nter nati o nal 
n or malize d rati o 
(I N R)  
Cli nical 
C he mistr y 1 Bl o o d urea nitr o ge n  P otassi u m  A S T/ Ser u m gl uta mic -
o xal oacetic 
tra nsa mi nase  T otal bilir u bi n  
 Creati ni ne  S o di u m  A L T/ Ser u m gl uta mic -
p yr u vic tra nsa mi nase  T otal pr otei n  
 Al kali ne p h os p hatase  C P K    
Efficac y 
Bi o mar kers  Cell -free D N A  
Citr ulli nate d hist o ne 
H 3 
M yel o per o xi dase 
( M P O) -D N A 
c o m ple xes  I L -1 beta  
I L - 6 
I L - 8 
T N F -al p ha De s m o si ne  
 
C- Reacti ve Pr otei n  D-Di mer  
Fi bri n o ge n 
Pr ocalcit o ni n  
 
P K  Pre or 1-2 hrs  P ost d ose     
Ot her Scree ni n g 
a n d i n St u d y 
Tests  • Uri ne pre g na nc y test d uri n g t he st u d y (as nee de d f or w o me n of c hil d beari n g p ote ntial)  
• Ser u m  h u ma n  c h ori o nic  g o na d otr o pi n  pre g na nc y  test  (as  nee de d  f or  w o me n  of 
c hil d beari n g p ote ntial)  
• All st u d y -re q uire d la b orat or y assess me nts will be perf or me d at t he l ocal la b orat or y, 
wit h t he e xce pti o ns of t he bi o mar ker efficac y (see Secti o n 9. 2 ) a n d P K sa m ples w hic h 
will be se nt t o a ce ntral la b orat or y f or c urati o n a n d a nal ysis.  
• T he res ults of eac h test m ust be e ntere d i nt o t he C R F  
1 Details of li ver c he mistr y st o p pi n g criteria a n d re q uire d acti o ns a n d f oll o w -u p assess me nts after li ver st o p pi n g or  
m o nit ori n g e ve nt are gi ve n i n Secti o n 8. 1 . All e ve nts of A L T 3 × U L N a n d bilir u bi n 2 × U L N ( > 3 5 % direct 
bilir u bi n) or A L T 3 × U L N a n d I N R > 1. 5, if I N R is meas ure d, w hic h ma y i n dicate se vere li ver i nj ur y ( p ossi ble 
H y’s La w), m ust be re p orte d as a n S A E. 2 L ocal uri ne testi n g will be sta n dar d.  
 
I n v esti gat ors m ust d oc u me nt t heir re vie w of eac h la b orat or y safet y re p ort.  
 Protocol Version 2.0 
 Page 54 of 70 APPENDIX 3:  STUDY GOVERNANCE CONSIDERATIONS  
Regulatory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with: 
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines . 
• Applicable International Conference on Harmonization ( ICH) Good C linical Practice 
(GCP) Guidelines. 
• Applicable laws and regulations under the IND. 
• The protocol, protocol amendments, ICF , Investigator ’s Brochure, and other relevant 
documents (e.g., advertisements) must be submitted to an IRB  by the Investigator and 
reviewed and approved by the IRB & Competent Authority/Regulatory Authority before the 
study is initiated.   
• Any amendments to the protocol will require IRB approval before  implementation of 
changes made to the study design, except for changes necessary to elimi nate an immediate 
hazard to study participants.  
• The Investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB annually or more frequently in accordance with the requirements, policies, and pr ocedures established 
by the IRB. 
• Notifying the IRB of SAE s or other significant safety findings as required by IRB 
procedures. 
• Overall conduct of the study at the site and ad herence to requirements of 21 CFR, 
ICH guidelines, the IRB, and all other applicable local regulations. 
Financial Disclosure  
Principal Investigators and Site Investigators  will provide the Sponsor with sufficient, accurate 
financial information in accordan ce with local regulations to allow the Sponsor to submit 
complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities.  Investigators are responsible for providing information on financial 
interests during the course of the study and for 1 year after completion of the study. 
 Protocol Version 2.0 
 Page 55 of 70 Informed Consent Process  
• The Site Investigator or his/her representative will explain the nature of the study to the 
participant  or his/her legally author ized representative and answer all questions regarding the 
study.  
• Participant s must be informed that their participation is voluntary. Participant s will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA ) requirements, where applicable, and the IRB or study site .  
• The source documentation and CRF must include a statement that written informed consent 
was obtained before the participant  was enrolled in the study and the date the written consent 
was obtained. The author ized person obtaining the informed consent must also sign the ICF. 
• Participant s must be re-consented to the most current version of the ICF(s ) during their 
participation in the study. 
• A copy of the ICF(s)  must be provided to the participant  or his/her legally author ized 
representative.  
Data Management 
• The study will use an electronic data capture system  
• Site Investigator / Site PI will be responsible for data entry into the system.   
• Oversight for the study will be done via risk-based monitoring. 
• If adverse events require re-hospitalization, study participants will be cared for by the 
hospital staff at the local sites as per local policy. The study team will monitor the status of 
the patient while hospitalized, but will not be required to provide all aspects of care for these individuals. 
Data Protection 
• Participants will be assigned a unique identifier. A ny participant records or datasets will 
contain the identifier only; participant names or any information that would make the 
participant identifiable will not be transferred.  
• The participant must be informed that his/her personal study- related data will be used  in 
accordance with local data protection law. The level of  disclosure must also be explained to 
the participant.  
• The participant must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other author ized personnel appointed by UAB , Mereo 
BioPharma, by appropriate IRB members, and by inspectors from regulatory authorities. 
Data Quality Assurance 
• All participant  data relating to the study will be reco rded on printed or electronic CRF unless 
transmitted electronically ( e.g., laboratory data). The Investigator is responsible for verifying 
that data entries are accurate and correct by physically or electronically signing the CRF.  
 Protocol Version 2.0 
 Page 56 of 70 • The Investigator must maintain accurate documentation (source data) that s upports the 
information entered in the CRF.  
• The Investigator must permit study -related monitoring, audits, IRB review, and regulatory 
agency inspections and provide direct access to source data documents.  
• The Sponsor or designee is responsible for the data management of this study, including 
quality checking of the data.  
• Records and documents, including signed ICF, pertaining to the conduct of this study must 
be retained by the Investigator for 25 years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the NIH. No records may be transferred 
to another location or party without written notification  to the IRB. 
Source Documents  
• Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. Source documents are filed at the Investigator ’s site.  
• Data reported on the CRF or entered in the e lectronic CRF  that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfe r records, 
depending on the study. A lso, current medical records must be available.  
• Definition of what constitutes source data can be found in the Study Manual and Monitoring Plan. 
Study and Site Closure  
UAB,  the FDA, the IRB,  or a designee may stop the study or study site participation in the study 
for medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, regulations, and GCP.  
 Protocol Version 2.0 
 Page 57 of 70 APPENDIX 4:  ADVERSE EVENTS: DEFINITI ONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW -UP, AND REPORTING  
AE Definition  
• An AE is any untoward medical occurrence in a clinical trial subject administered a medicinal 
product and which does not necessarily have a causal relationship with this treatment.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of a medicinal product.  
 
Events Meet ing the AE Definition   
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments ( e.g., EKG, radiological scans, vital signs measurements), including those 
that worsen from baseline, considered  clinically significant in the medical and scientific 
judgment of the Investigator ( i.e., not related to progression of underlying disease). 
• Exacerbation of a chronic or intermittent pre -existing  condition including either an increase in 
frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after study treatment administration even though it may have been present before the start  of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a 
concomitant medication . Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be 
reported regardless of sequelae. 
• “Lack of efficacy ” or “failure of expected pharmacological action” per se will not be reported as 
an AE/SAE.  Such instances will be captured in the efficacy assessments.  However, the signs, 
symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE /SAE  if 
they fulfil the definition of an AE/ SAE.  
 
Events NOT Meeting the AE Definition   
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments 
which are associated with the underlying disease, unless judged by the Investigator to be more severe than expected for the participant ’s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant ’s condition. 
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the 
procedure is the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospital). 
• Anticipated day -to-day fluctuations of pre -existing  disease(s) or condition(s) present or detec ted 
at the start of the study that do not worsen. 
 Protocol Version 2.0 
 Page 58 of 70  
Unanticipated Problem  (UP)  Definition  
• In general, an AE observed during the conduct of a study should be considered an 
Unanticipated Problem (UP)  involving risk to human subjects, and reported to the IRB, only if 
it were unexpected, serious, and would have implications for the conduct of the study (e.g., 
requiring a significant, and usually safety-related, change in the protocol such as revising inclusion/exclusion criteria or including a new monitoring requirement, informed consent, or investigator’s brochure).   
• An individual AE occurrence ordinarily does not meet these criteria because, as an isolated event, its implications for the study cannot be understood.  
• AEs listed in the Investigator’s Brochure (IB) are not by definition UPs because they have been previously observed with a drug and would not be considered unexpected and thus would not be unanticipated problems.  
• Possible exceptions would include situations in which the specificity or severity of the event is not consistent with the description in the investigator’s brochure, or it can be determined that the observed rate of occurrence for a serious, expected AE in the clinical trial  represents a clinically 
important increase in the expected rate of occurrence. 
 
Events Meeting UP Definition   
• A single occurrence of a serious, unexpected event that is uncommon and strongly associated 
with drug exposure (such as angioedema, agranulocytosis, hepatic injury, or Stevens-Johnson syndrome).  
• A single occurrence, or more often a small number of occurrences, of a serious, unexpected event that is not commonly associated with drug exposure, but uncommon in the study population (e.g., tendon rupture, progressive multifocal leukoencephalopathy).  
• Multiple occurrences of an AE that, based on an aggregate analysis, is determined to be an unanticipated problem. There should be a determination that the series of AEs represents a signa
l 
that the AEs were not just isolated occurrences and involve risk to human subjects (e.g., a comparison of rates across treatment groups reveals higher rate in the drug treatment arm versus a control).  
• An AE that is described or addressed in the investigator’s brochure, protocol, or informed 
consent documents, but occurs at a specificity or severity that is inconsistent with prior 
observations. For example, if transaminase elevation is listed in the investigator’s brochure and hepatic necrosis is observed in study subjects, hepatic necrosis would be considered an unanticipated problem involving risk to human subjects.  
• A serious AE that is described or addressed in the investigator’s brochure, protocol, or informed consent documents, but for which the rate of occurrence in the study represents a clinically significant increase in the expected rate of occurrence (ordinarily, reporting would only be triggered if there were a credible baseline rate for comparison).  
• Any other AE or safety finding (e.g., based on animal or epidemiologic data) that would cause the sponsor to modify the investigator’s brochure, study protocol, or informed consent documents, or would prompt other action by the IRB to ensure the protection of human subjects. 
 Protocol Version 2.0 
 Page 59 of 70 Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met ( e.g., hospitalization for signs/symptoms of the disease under study, death due to 
progression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  or; 
b. Is life -threatening  or; 
The term “life-threatening ” in the definition of “serious” refers to an event in which the participant  
was at risk of death at the time of the event.  It does not refer to an event, which hypothetically might 
have caused death, if it were more severe.  
c. Requires  inpatient  hospitali zation or prolongation of existing hospitali zation  or; 
In general, hospital ization signifies that the participant has been detained (usually involving at least 
an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not 
have been appropriate in the physician’s office or out patient setting.  Complications that occur during 
hospitaliz ation are AE s. If a complication prolongs hospitali zation or fulfils any other serious criteria, 
the event is serious. When in doubt as to whether “hospitali zation” occurred or was necessary, the A E 
should be considered serious. 
Hospitaliz ation for elective treatment of a pre -existing condition that did not worsen from baseline is 
not considered an AE. 
d. Results in persistent disability/incapacity  or; 
• The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions. 
• This definition is not intended to include experiences of relatively minor medical significance 
such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, and accidental trauma 
(e.g., sprained ankle) that may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption . 
e. Is a congenital anomaly/birth defect  or; 
f. Other situations:  
• Medical or scientific judgment should be exercised  in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may not be immediately life -
threatening or result in death or hospitali zation but may jeopardi ze the participant  or may require 
medical or surgical intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually be considered serious. 
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospitalization, or development of drug dependency or drug abuse. 
 
 Protocol Version 2.0 
 Page 60 of 70 Recording AE s and SAE s 
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation 
(e.g., hospital progress notes, laboratory, and diagnostics reports) related to the event.  
• The Investigator will then record all relevant AE/SAE information in the CRF. 
• It is not acceptable for the Investigator to send photocopies of the participant’s medical records 
to the Safety Reporting Group in lieu of completion of the AESI /AE/SAE CRF page.  
• There may be instances when copies of medical records for certain cases are requested by the 
Safety Reporting Group. In this case, all participant identifiers, with the exception of the 
participant  number, will be blinded on the copies of the medical records before  submission to the 
Safety Reporting Group 
• The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. In such cases, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE . 
Assessment of Intensity  
The Investigator  will make an assessment of intensity for each AE and SAE reported during the study 
and assign it to one of the following categories:   
• Mild: An event that is easily tolerated by the participant , causing minimal discomfort and not 
interfering with everyday activities.  
• Moderate:  An event that causes  sufficiently discomfort and interferes with normal everyday 
activities . 
• Severe:  An event that prevents normal everyday activities. A n AE that is assessed as severe 
should not be confused with an SAE. Severe is a category util ized for rating the intensity of an 
event; and both AEs and SAE s can be assessed as severe.  
• An event is defined as “serious” when  it meets at least one of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.  
Assessment of Causality  
• The Investigator  is obligated to assess the relationship between study treatment and each 
occurrence of each AE/SAE.  
• A “reasonable possibility” of a relationship conveys that there are facts , evidence, and/ or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
• The Investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as 
well as the temporal relationship of the event to study treatment administration will be 
considered and investigated. 
• The Investigator will also consult the Investigator ’s Brochure and/or Product Information, for 
marketed products, in his/her assessment. 
• For each AE/SAE , the Investigator must  document in the medical notes that he/she has reviewed 
the AE/SAE and has provided an assessment of causality. 
 Protocol Version 2.0 
 Page 61 of 70 • There may be situations in which an SAE has occurred and the Investigator  has minimal 
information to include in the initial report to.  However, it is very impor tant that the 
Investigator always make an assessment of causality for every event before the initial 
transmission of the SAE data to the Safety Reporting Group. 
• The Investigator may change his/her opinion of causality in light of follow-up information and 
send an SAE follow-up report with the updated causality assessment. 
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
Follow -up of AE and SAE  
• The Investigator  is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by the Safety Reporting 
Group to elucidate the nature and/or causality of the AE or SAE  as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals. 
• If a participant dies during participation in the study or during a recognized  follow-up period, the 
Investigator will provide the Safety Reporting Group with a copy of any postmortem findings 
including histopathology. 
• New or updated information will be recorded in the originally completed CRF. 
• The Investigator will submit any  updated SAE data to the Safety Reporting Group within 24 
hours of receipt of the information . 
SAE Reporting   
• SAEs will be reported to the safety reporting group  using a paper based system  
• Contacts for safety reporting can be found in the COSTA Site File  
• Initial reporting can be updated when additional information is obtained but this should not delay 
submission. 
 
Suspected Unexpected Serious Adverse Reaction (SUSAR)  
• An adverse reaction (AR) is any untoward or unfavorable medical occurrence in a cli nical 
research study participant, including any abnormal sign (e.g. abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participants’ involvement in the research, whether or not considered related to participation in the research. 
• An adverse event or suspected adverse reaction is considered “unexpected” if it is not listed in 
the investigator brochure or is not listed at the specificity or severity that has been observed. 
• SUSAR events are AR events that fulfil criteria for seriousness (outlined in SAE above).  
SUSARs should be reported to the safety reporting group, Mereo  BioPharma , and the FDA using 
the instructions listed for SAE reporting. 
 
 Protocol Version 2.0 
 Page 62 of 70 APPENDIX 5:  CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY 
INFORMATION 
Alvelestat has a low genotoxic potential and reproductive toxicology studies have not 
demonstrated any effects in either the reproductive function or in embryo-fetal development. Therefore, the following precautions are required to protect women of childbearing potential and female partners of males in the study.  
It is expected that participants with COVID -19 will avoid becoming pregnant or fathering a child 
during the acute infection and that abstinence will be the expected form of contraception. 
However, full guidance is given below. 
Definitions  
Woman of Childbearing Potential  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile. Permanent steriliz ation methods include hysterectomy, bilateral 
salpingectomy, and bilateral oophorectomy. 
Women in the following cate gories are not considered wome n of childbearing potential  
 
1) Premenopausal female with one of the following: 
a) Documented hysterectomy  
b) Documented bilateral salpingectomy  
c) Documented bilateral oophorectomy 
Note: Documentation can come from the site personnel’s: review of participant’s medical 
records, medical examination, or medical history interview. 
2) Premenarchal  
3) Postmenopausal female  
a) A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormone replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, a single follicle stimulating hormone measurement is 
insufficient.  
b) Females on HRT and whose menopausal status is in doubt will be required to use 1 of the 
non-hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrolment. 
 Protocol Version 2.0 
 Page 63 of 70 Contraception Guidance  
Male pa rticipants  
Male participants with female partners of childbearing potential are eligible to participate if they 
agree to the following:  
1) Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle (abstinent 
on a long-term and persistent basis) and agree to remain abstinent for duration of study and for 4 days from last dose  
2) Female partner is using a highly effective contraceptive method  
3) Agree to use a male condom plus an additional method with a failure rate of <1% per year as described in the table below when having penile-vaginal intercourse with a woman of childbearing potential.   
4) Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration and for 4 days from last dose. 
Highly Effective Contraceptive Methods That Are User Dependent   
Failure rate of <1% per year when used consistently and correctlya.  
 Combined (estrogen and progestogen -containing) hormonal contraception associated with inhibition of 
ovulationb  
• Oral  
• Intravaginal  
• Transdermal  
 Progestogen -only hormonal contraception associated with inhibition of ovulationb  
• Oral  
• Injectable  
Highly Effective Methods That Are User Independent   
• Implantable progestogen -only hormonal contraception associated with inhibition of ovulationb 
• Intrauterine device (IUD) 
• Intrauterine  hormone- releasing system (IUS)  
• Bilateral tubal occlusion  
 Vasectom ized partner  
(A vasectomized  partner is a highly effective contraception method provided that the partner is the sole male 
sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, 
an additional highly effective method of contraception should be used.)   
 Sexual abstinence  
(Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study treatment . The reliability of sexual 
abstinence needs to be evaluated in relat ion to the duration of the study and the preferred and usual lifestyle 
of the participant.)   
 Protocol Version 2.0 
 Page 64 of 70 NOTES:  
a) Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with 
local regulations regarding the use of contraceptive methods for participants participating in clinical studies.  
b) Hormonal contracepti on may be susceptible to interaction with the study treatment , which may reduce the efficacy of 
the contraceptive method. In this case, 2 highly effective methods of contraception should be util ized during the 
treatment period and for at least 4 days from last dose.   
 
Female participants  
Female participant s of reproductive potential are eligible to participate if they agree to use a 
highly effective method of contraception consistently and correctly as described in the table 
above.  
Pregnancy Testing  
Women of childbearing potential  should only b e included a fter a negati ve highly sensitive serum 
pregnancy test. 
Additional pregnancy testing should be performed at regular int ervals as per the SoA 
Pregnancy testing, with a sensitivity of 5 mIU/mL will be performed and assayed at the study 
site.  
Collec tion of Pregnancy Information  
Male participant s with partners of reproductive potential who become pregnant  
Investigator will attempt to coll ect pregnancy info rmation on any fe male partner of a male stu dy 
participant who bec omes p regnant whil e participating in this s tudy. This applies only to 
participants who re ceive stu dy tr eatment. 
If a pregnancy is reported for a subject’s partner, study treatment will be immediately 
discontinued.  
After obtaining the ne cessary signed ICF  from t he pre gnant fe male p artner directly, th e 
Investigator will r ecord p regnancy inf ormation on the appropria te form wi thin 24 hours of 
learning of the pa rtner’s pregnancy. 
Partner will also be followed to determine the outcome of the pre gnancy . Information on the 
status of the mo ther and chil d will be fo rwarded to the Safety Reporting Group. 
Generally, follow-up will be no longer than 6 to 8 w eeks following the e stimated delivery da te. 
Any te rmin ation of the pregnanc y will be r eported reg ardless of f etal status (p resence or absenc e 
of anomalies) or indication for p rocedu re. 
 Protocol Version 2.0 
 Page 65 of 70 Female participants who become pregnant  
Investigator will colle ct pregnancy in formation on any fe male participant who becomes pregnant 
while participating in this s tudy. 
Information wil l be recorded on the appropri ate form and submit ted to  the Safety Reporting 
Group with in 24 hours of le arning of a participant's p regnancy. 
Participant will be follow ed to determine the outco me of the p regnancy. Th e Investigator will 
collect follow -up inf ormation on pa rticipant and neona te, which will be fo rwarded to the Safety 
Reporting Group. Generally, follow-up will not be re quired for longer than 6 to 8 w eeks beyond 
the estimated delivery da te. 
Any te rmin ation of pregnanc y will be r eported, re gardless of fetal status (presenc e or absenc e of 
anomalie s) or ind ication for procedure. 
Whil e pregnancy itself is not conside red to be an AE or SAE, any pre gnancy compl ication or 
elective termin ation of a pre gnanc y will be reported as an AE or SAE.  
A spontaneous abortion i s always considered to be an S AE and will be repo rted as such. 
Any S AE occ urring a s a result of a post- study pregnancy that is considere d reasonably re lated to 
the stu dy treatment b y the Investigator will be r eported to the Safety Reporting Group a s 
described in Appendix 4 . While the Investigator is not obligated to actively seek thi s info rmation 
in former stu dy pa rticipants, he/ she m ay learn of an S AE through spontaneous reporting. 
Any fe male participant who becomes p regnant whil e participating will be withdrawn from the 
study.
 Protocol Version 2.0 
 Page 66 of 70 APPENDIX 6:  WORLD HEALTH ORGANISATION 9 -POINT ORDINAL SCALE  
WHO 9 -point ordinal scale: 
0. Uninfected, no clinical or virological evidence of infection  
1. Ambulatory, no limitation of activities  
2. Ambulatory, limitation of activities  
3. Hospitalized  – mild disease, no oxygen therapy 
4. Hospitalized  – mild disease, oxygen by mask or nasal prongs 
5. Hospitalized  – severe disease, noninvasive ventilation or high flow oxygen 
6. Hospitalized  – severe disease, intubation and mechanical ventilation 
7. Hospitalized  – severe disease, ventilation and additional organ support – vasopressors, 
renal replacement therapy (RRT ), extracorporeal membrane oxygenation (ECMO) 
8. Death  
 
 Protocol Version 2.0 
 Page 67 of 70 APPENDIX 7:  COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS   
 (CTCAE) v5.0 Publish Date: November 27, 2017 
 
1 CTC AE v5.0 incorporates certa in elemen ts of the Med DRA termi nology. For further details on Med DRA refer to the Med DRA MSSO  Web site (h ttps://www. meddra.org/) .

 Protocol Version 2.0 
 Page 68 of 70 APPENDIX 8:  STUDY ORGANIZATION 
UAB  Name  Title  Contact  
Study PI, Medical 
Oversight Mike Wells, MD  Associate Professor  +1 205 996  0101 
jmwells@uabmc.edu  
Sub-Investigator  Mark Dransfield, MD  Professor  +1 205 996  0101 
mdransfield@uabmc.edu 
Mereo BioPharma   
Mereo BioPharma 
Medical Expert Jackie Parkin  Therapeutic Area Head  jp@mereobiopharma.com 
Mereo BioPharma 4 Ltd. 
1 Cavendish Place London, W1G 0QF 
United Kingdom 
Clinical Operations  William Moore  Director, Clinical 
Operations wm@mereobiopharma.com 
Mereo BioPharma 4 Ltd. 
1 Cavendish Place 
London, W1G 0QF 
United Kingdom 
Safety Scientist  Adzoa Ekue Safety Scientist  adzoa.ekue@mereobiopharma.com 
Mereo BioPharma 4 Ltd. 
1 Cavendish Place 
London, W1G 0QF 
United Kingdom 
Syneos Health  
Safety Reporting 
Group Jelena Jevtović Safety Specialist, 
Safety and 
Pharmacovigilance  jelena.jevtovic@syneoshealth.com 
OR 
safetyreporting@syneoshealth.com  
Proto col Version 2.0 
Page 69 of 70 APPENDIX 9:  SUMMARY OF VERSIONS AND CHANGES  
Summary of Versions: 
Protocol  Version  Date  Summary of Change  
Original 1.0 August 12, 2020 Not Applicable 
Amendment 1.0 2.0 April 20, 2021 •CPK testing has been added to Appendix 2
(Safety and Efficacy Parameters) in the
protocol as requested by FDA
•Dosing to Day 5 with optional extension toDay 10
•Removal of study drug dose escalation
•Administrative corrections and formattingchanges
Proto
col Amendment 1 Summary of Changes: 
Protocol Amendment 1 Changes Sections Applied Rationale  
Primary endpoint mortality rate to 
day 90 moved as secondary endpoint 
and clarified as a safety endpoint Objectives and 
Endpoints To enable unblinding at Day 60 for 
development decision, Mortality hard 
endpoint not expected to be impacted by 
unblinding  
Study design change from a 10  day 
dosing regime to a 5 day dosing 
regime with extension to 10 days for 
those still hospitalized at Day 5  Overall Purpose 
and Design: 
Objectives and 
Endpoints: and 
throughout  To account for changes in outcomes for 
patients with COVID where the mean 
hospital stay is now 5 days, whilst 
allowing for extension to 10 days for 
those whose disease has not resolved  
Safety endpoints moved from Day 10 
and Day 14 to Day 5 and Day 10 
throughout Overall Purpose 
and Design: 
Objectives and 
Endpoints: and 
throughout  To reflect the inclusion of a 5 day dosing 
regime with optional extension to 10 
days 
Early efficacy endpoints changed 
from Days 7, 10, 14 to Days 5 and 10 
throughout Overall Purpose 
and Design: 
Objectives and 
Endpoints:  To reflect the inclusion of a 5 day do sing 
regime with optional extension to 10 
days 
Table amended to reflect changes in 
study safety and efficacy assessments Schedule of 
Assessments  Due to reduction in study drug dosing 
period from 10 to 5 days  
End of treatment safety follow -up 
visit window increased from +/-1 day 
to +/-2 days  Schedule of 
Assessments Increased flexibility for discharged 
patients to attend hospital  
Proto col Version 2.0 
Page 70 of 70 Protocol Amendment 1 Changes Sections Applied Rationale  
Removal of study drug dose 
escalation steps to initiate alvelestat 
at dose of 240 mg bid or placebo 
from Day 1  Schedule o f 
Assessments; 
Study Design; 
Treatments 
Administered  For faster time to required alvelestat 
levels for rapid maximal anti-
inflammatory effect and in light of 
absence of safety/ toleration issues and 
protocolized dose de- escalation if 
needed  
Reduction of EK G and PK 
assessments Schedule of 
Assessments Removal of EKG and PK at dose 
escalation steps in line with removal of 
dose escalation  
Multiple changes  Schedule of 
Assessments Multiple updates for clarification of 
activities to align with other changes 
outlined in this table  
Changes to Study Schematics  Study Schematic  To reflect changes in study design to a 
5 day dosing regime with extension to 
10 days  
Addition of use of antigen testing for 
SARS -CoV-2 for diagnosis Inclusion Criteria; 
Key Screening 
Assessments  To reflect current medical practice  
Addition of other COVID -19 
therapies, including antibody 
treatment  Exclusion Criteria  To reflect current medical practice  
Addition of CPK testing  Appendix 2: 
Clinical 
Laboratory Tests  As requested by the FD A 
Various updates to study organization  Appendix 8: Study 
Organization  Updates and corrections to study 
organization  
Formatting changes  Throughout  To improve readability  